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ABSTRACT 
ENVIRONMENTAL RISK FACTORS FOR INFLAMMATORY BOWEL 
DISEASE: TRICLOSAN AND OTHER CONSUMER ANTIMICROBIALS 
 
SEPTEMBER 2019 
 
KATHERINE ZABALA SANIDAD, B.S., STONY BROOK UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Guodong Zhang 
 
 
Inflammatory bowel disease (IBD) has become a serious health problem since the 
incidence and prevalence of IBD has dramatically increased throughout the world. There 
is evidence that environmental factors are primarily responsible for the increase of IBD, 
therefore, it is important to identify novel environmental risk factors to reduce the risk of 
IBD and its associated diseases. Antimicrobials used in consumer products might serve as 
environmental risk factors for IBD and its associated diseases. Triclosan (TCS), 
triclocarban (TCC), benzalkonium chloride (BAC), benzethonium chloride (BET), and 
chloroxylenol (PCMX) are widely used antimicrobial ingredients in consumer products 
and are ubiquitous contaminants in the environment. In 2016, the FDA removed TCS and 
TCC from over-the-counter handwashing products while allowing additional time to 
develop new safety and efficacy data for BAC, BET, and PCMX. Therefore, it is 
important and timely to better understand the effects of these antimicrobials on human 
health. Currently, there not much known about how chronic exposure to low-dose 
consumer antimicrobials affects gut health. Here, using various in vitro and animal 
models, we found that: 1) TCS is metabolically re-activated in the gut by the actions of 
gut microbiota, leading to the accumulation of microbiota-derived toxic metabolites in 
viii 
the colon and resulting in gut-specific toxicity; 2) exposure to low-dose TCC exaggerated 
the severity of colitis and exacerbated the development of colitis-associated colon 
tumorigenesis, via gut microbiota-dependent mechanisms; and 3) exposure to low doses 
of BAC, BET, and PCMX, increases dextran sodium sulfate (DSS)-induced colonic 
inflammation and  exposure to BAC increases azoxymethane (AOM)/DSS-induced colon 
tumorigenesis in mice. Together, these results support that chronic exposure to consumer 
antimicrobials could be a novel risk factor for colitis and colitis-associated colon cancer 
through gut microbiota-dependent mechanisms. A better understanding of the impact 
antimicrobials on human health, specifically gut health, could lead to significant 
influence on public health and regulatory policies.  
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1 
CHAPTER 1 
INTRODUCTION 
1.1 Environmental risk factors for inflammatory bowel disease 
Inflammatory bowel disease (IBD), characterized by chronic inflammation within 
the small and large intestines, has become a serious health problem. The incidence and 
prevalence of IBD has dramatically increased in the United States and other countries, 
and currently there is no cure for IBD 1. Another concern for IBD patients is that they 
have an increased risk for developing colon cancer. In fact, more than 20% of IBD 
patients will develop and more than 50% of those patients will die from colon cancer 2. 
There is evidence that environmental factors are primarily responsible for the increase of 
IBD 3-5;  therefore, it is important to identify novel environmental risk factors to reduce 
the risk of IBD and its associated diseases.  
One environmental factor suggested to increase IBD are antimicrobial agents 
through modulation of the gut microbiome. It is well established that oral antibiotic 
drugs, at therapeutic doses, can modulate gut microbiota to regulate colonic inflammation 
6,7. However, it is not known how chronic exposure to low-dose consumer antimicrobials 
affects gut health. Here, we will focus on the consumer antimicrobials triclosan (TCS), 
triclocarban (TCC), benzalkonium chloride (BAC), benzethonium chloride (BET), and 
chloroxyenol (PCMX) (see chemical structures in Figure 1). We will discuss their 
exposure into the environment as well as their effects on the gut microbiome and gut 
health in animal models and humans.  
  
  
 
2 
1.2 Antimicrobials in the consumer products and the environment 
During the past two decades, antimicrobial-containing products have increased in 
the U.S. and other countries 8. The two most common antimicrobials highly produced are 
triclosan (TCS) and triclocarban (TCC). TCC was introduced in 1957 as an antifungal 
and antibacterial compound specifically used against resistant forms of Staphylococcus 
aureus (MRSA) and Enterococci (VRE) 8. Later in 1964, TCS was introduced as a broad-
spectrum bacteriostatic and fungicidal agent. TCS has antimicrobial activity due to its 
inhibition of the FabI enzyme which inhibits fatty acid synthase in microorganisms 9. 
TCC and TCS are incorporated into consumer products like soap, toothpaste, mouthwash, 
clothes, kitchenware, and toys. They are also used in deodorants, polymers, and fibers 10.  
When antimicrobial compounds are typically disposed, they usually are 
transported through drainage systems to wastewater treatment plants (WWTPs) where 
they can be removed from water that will end up being discharged into surface waters 8. 
When released into the environment, TCS has been shown to be transformed into methyl-
TCS by certain bacteria such as Rhodococcus, Acinetobacter, and Mycobacterium under 
aerobic conditions, and TCS can also go through photodegradation 11-14.  
Despite their fates in WWTPs, TCS and TCC have been reported to break through 
WWTPs to disperse into surface waters at ng/L concentrations. In addition, the two 
antimicrobials are can also accumulate in carbon- and lipid-rich sewage sludge, which is 
then deposited in landfills or applied onto land 15. Because of this, TCS and TCC has 
been detected in the environment in the United States and various other countries. In 
2014, they were known to be part of the top 10 contaminants in U.S. rivers 8. TCS has 
been detected in Indiana stream waters 16. In Germany, TCS and methyl-TCS was 
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detected in the surface water, fish, and suspended particulate matter in rivers 17,18. TCS 
has been found in the surface waters of Washington D.C. and Switzerland 19,20. Both TCS 
and TCC were also detected in the soil of fields that receive sewage sludge in Ohio and 
the United Kingdom 13,21. They were also detected in earthworms and biosolids in 
Ottowa, Canada 22. TCS can also be detected in biosolids in North Carolina and 
California that could be potentially used for farming 23. TCC has been detected in Lake 
Greifensee sediments in Switzerland 24. 
Both TCS and TCC appear to last long in the environment. TCS detected in the 
surface water in Germany was found to have an 11 day half-life 17,18. Another study 
showed that the TCS and TCC that were detected in field soil had a half-life of 20-58 
days and may last even longer 13,21. Interestingly, TCC, TCS, and methyl-TCS were 
detected in earthworms four years after applying TCS- and TCC- containing biosolids 
into an environment in Ottowa, Canada 22.  
Due to their widespread contamination and longevity in the environment, TCS 
and TCC were detected in both aquatic life and food crops. TCS was found in salmon 
25,26 while TCC was absorbed by freshwater mussels 27. Both TCS and TCC have been 
reported to accumulate in crops and vegetables like soybean plants that were planted in 
contaminated soil and irrigated with contaminated water 28-31. TCS and TCC were also 
found in the roots and shoots of crops such as broccoli, potato, beats, cabbages, and 
peppers. The root tissues of the plants accumulated greater than 100 ppm TCC, while 
onions accumulated greater than 800 ppm in their bulbs. TCS and methyl-TCS was found 
in the roots of certain vegetables 32.  
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Benzalkonium chloride (BAC), benzethonium chloride (BET), and chloroxylenol 
(PCMX) are other antimicrobial compounds that are potential replacements of TCS and 
TCC in consumer products. BAC, BET, and PCMX are antimicrobial ingredients used in 
many cleaning products and surface disinfectants that are widely used in public spaces 
including workspaces, hospitals, and homes 33,34. They are also used in hand hygiene or 
skin antiseptics, with concentrations of 250-500 mg/L 34-36. In addition to being used in 
hand soaps and dish soaps, PCMX has also been used as a pesticide 34. Previous studies 
have shown that BAC and BET were also frequently detected at high levels in grapefruit 
seed extract (GSE), a common dietary supplement, with 5 out of 6 commercial GSE 
products containing 1.3-10% of BET37,38. Because of the widespread use of these 
compounds, BAC and BET were also detected in various environments. They were 
detected in river water, sewage effluent, urban estuarine sediment, and stormwater 
samples 39-41. The release of these antimicrobials into the environment raise concerns 
regarding their exposure to and impacts on human health and the environment 37-45. 
1.3  Human exposure to antimicrobials 
Various antimicrobials have been detected frequently detected in the human body. 
Between 2003-2004, TCS was detected in 75% of urine samples of individuals in the 
United States (TCS concentration = 7.9 nM-13.1 µM) 46. TCS has also been detected in 
urine samples (TCS concentration = 0.08-0.71µM) in Queensland, Australia 47 and in 
Quebec, Canada 48. In 2013-2014, 36.9% of urine samples in the United States contained 
>0.1 µg/L of TCC 49. Both TCS and TCC were detected in the urine samples of people in 
China 50 as well as in the serum of women 51. TCC reportedly reached a concentration of 
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~500 nM in the plasma of humans using TCC-containing personal care products 52. Both 
TCS and TCC were also found in the blood of pregnant women and their newborns in an 
urban population from Brooklyn, NY 53 and in the urine of pregnant women in Canada 54. 
BAC has also been detected in the serum of a patient who accidentally ingested the 
antimicrobial 43. There have been no recent studies about whether BET or PCMX have 
been found in humans, but that may change with the increase use of these antimicrobials. 
The average human intake levels of TCS from using consumer products was 
estimated to be 0.047-0.073 mg/kg/day; in mice it would be equivalent to 0.56-0.88 
mg/kg. Men, women, and children, are exposed to 0.047, 0.065, and 0.073 mg/kg/day, 
respectively 55. Data from previous studies was used to extrapolate TCS tissue exposure 
levels from consumer products: according to data from two studies, dermal exposure to 
TCS can lead to 0.4-64 nmol TCS/mg tissue 56-58. Because antimicrobials are found quite 
often in human tissues, it is important to understand different routes by the compounds 
that might lead to human exposure.   
Because TCS is used in certain toothpastes, exposure to the antimicrobial can 
occur orally in humans 26. Previous human studies had shown that using TCS-containing 
toothpaste daily for weeks increased the plasma concentrations of TCS (a combination of 
TCS and TCS-glucuronide) from 0.03–2.7 nM to 90–1,000 nM 59,60. Other studies also 
showed that oral exposure to TCS via TCS-containing toothpaste or mouth rinse can 
increased plasma levels of TCS in human subjects 61,62. Interestingly, a study showed that 
mothers using TCS-containing toothpaste for 6-12 weeks had 0.4-38 ng/g TCS (a 
combination of TCS and its conjugates, TCS-sulfate and TCS-glucuronide) in their 
plasma and 0.022-0.95 ng/g TCS in their breast milk 63; this suggests that the young 
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infants being breastfed by those mothers can be orally exposed to TCS. In fact, two 
studies reported that infants were orally exposed to TCS via the breast milk of mothers 
exposed to TCS-containing personal care products 64,65.  
Oral exposure to antimicrobials might also occur via food consumption. As 
mentioned before, TCS and TCC has been reported to accumulate in crops and vegetables 
28. TCC was also shown to be uptaken by freshwater mussels 27. TCS, TCS-conjugates 
(TCS-glucuronide, TCS-sulfate), and methyl-TCS found in catfish, salmon, and other fish 
18,25,66. BAC was found in food additives in minced meat and raw sausage batters 44. 
Previous studies have shown that BAC and BET were frequently detected at high levels 
in grapefruit seed extract (GSE), which is a common dietary supplement, though these 
compounds are not permitted to use as food additives 37,38. This suggests that suggests 
humans can be exposed to antimicrobials via the consumption of food and dietary 
supplements.  
Antimicrobials are also found in many different consumer products for topical 
application. TCS is in deodorants thus allowing people to be exposed to the antimicrobial 
via their skin 67. TCS absorption into the body can occur through dermal exposure as 
shown in an in vitro study using human epidermal membranes 68. Another study also 
showed TCS absorption through dermal exposure with TCS on human skin reaching 
millimolar levels 57,69. The estimated TCS concentration in tissues after dermal 
application is 14-67% of applied TCS dose 70.   
TCS and TCC were active ingredients in many soaps which would allow another 
route of dermal exposure; however, it was shown that TCS- and TCC-containing soaps 
had no additional health benefits compared to soap without those antimicrobials 71, and 
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were therefore no longer allowed to be sold.  The antimicrobials BAC, BET, and PCMX 
are still allowed in hand hygiene or skin antiseptics, such as hand and dishwashing soaps, 
suggesting a higher chance of dermal exposure to these compounds 34-36. They are also 
used in many cleaning products and surface disinfectants  33,34.  
Humans can ultimately be exposed to antimicrobials through the environment, use 
of antimicrobial-containing PCPs, as well as ingestion of certain food products. Because 
this exposure in humans is prominent, it is important to understand their effects on human 
health.  
1.4 Effects of antimicrobials on health 
There have been various in vitro and animal studies to understand the effects of 
antimicrobials on human health. In fact, many of these studies have focused on 
antimicrobials as endocrine disrupting chemicals; as agents that can facilitate 
developmental and reproductive defects; as toxicants that can increase genotoxicity, 
inflammation, and cancer; and as facilitators of antibacterial resistance to themselves as 
well as other antibiotics.   
Antimicrobials were shown to act as EDCs and increase developmental and 
reproductive defects. TCS and TCC have been shown to be endocrine disrupting 
chemicals (EDCs). In fact many studies have shown that both TCS and TCC can increase 
androgenic activity in various in vitro assays and animal models 72-77. One study even 
showed that TCC, TCS, and methyl-TCS can be EDCs in frog and mammalian cell 
culture systems 78. Exposure to TCS resulted in sperm toxicity in male rats 79, while 
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exposure to BAC and BET showed developmental defects in rodents and caused 
reproductive dysfunction in mice  80,81.  
Antimicrobials were also shown to increase genotoxic and inflammatory 
responses. Mice that were dermally exposed to TCS had increased immune cell 
infiltration into the skin draining lymph node, suggesting a potential for allergic reactions 
82. Previous studies have shown that BAC increased pro-inflammatory cytokines in 
immortalized human conjunctival and corneal epithelia cells 83, and also increased 
proinflammatory cytokines, phagocytosis, and migration in THP-1 macrophages 84. BAC 
also showed genotoxic and inflammatory effects in mammalian and plant cells and 
rainbow trout at environmentally relevant concentrations 85,86. As mentioned before, 
BAC, BET, and PCMX are three possible replacement antimicrobials for TCS and TCC. 
Interestingly, one study had shown that these three antimicrobials have comparable 
toxicities to TCS in C. elegans, greater toxicity in zebrafish embryos, and induce similar 
neurotoxicity to TCC in fish embryos 87. In addition, PCMX has been shown to cause 
DNA damage to erythrocytes of rainbow trout 88. 
TCS and TCC have been shown to increase the progression of certain cancers. 
TCS increased liver cancer in mice 89. TCS also increased ovarian cancer growth and the 
progression of breast cancer via an estrogen receptor-dependent pathway in cellular and 
mouse xenograft models 90,91. TCS can also increase cancer by potentiating the epithelial-
to-mesenchymal transition (EMT) in human lung cancer cells 92. TCS has also been 
shown to promote cancer by stimulating the secretion of vascular endothelial growth 
factor (VEGF) by human prostate cancer stromal cells 93. Chronic exposure to TCC was 
demonstrated to promote carcinogenesis of human breast cells in vitro from non-
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cancerous to pre-malignant 94, though more studies should be conducted to support its 
carcinogenic effects.  
Some antimicrobials have been associated with increased antibacterial resistance. 
A study showed that TCS can contribute to antimicrobial resistance in Escherichia coli 
strains 95. Another study showed that TCS can cause FabI mutations and antimicrobial 
resistance in MRSA, clinical isolates of Staphylococcus aureus, E. Coli, and 
Acinetobacter baumannii 96-100. TCS can also cause resistance to antibiotics in 
Pseudomonas aeruginosa by selecting for mutant strains overexpression multidrug efflux 
pumps 101. TCS exposure can increase its own resistance in benthic bacterial communities 
102,103. Aside from TCS, BAC and PCMX were also found to increase antibacterial 
resistance. BAC was found to increase cross-resistance in strains and isolates of Pantoea, 
Enterobacter, Staphylococcus, and Escherichia species to some antibiotics and other 
biocidal agents 104. Environmental isolates of staphylococci in Massachusetts were also 
found to be resistant to BAC, as well as erythromycin, penicillin, and ampicillin 105. In 
addition, BAC, used in disinfectants in the food industry, was well tolerated by Listeria 
monocytogenes isolates from some retail foods 106. PCMX was also tolerated and did not 
appear to have an effect on certain Pseudomonas species found in industrial 
environments 88. These results suggest that the application and exposure of these 
antimicrobials in the environment are associated with antibacterial resistance.  It would 
be interesting to see if the antimicrobials would increase antibacterial resistance in the gut 
microbiomes of animals and humans as well.  
There have also been a few human studies of the effects of these antimicrobials, 
mostly TCS. Human studies have shown and suggested that TCS exposure is associated 
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with allergies and asthma 107-109, which is supported by a study that showed TCS-induced 
aggravation airway hyperresponsiveness in aeroallergen-sensitized mice 110. Interestingly, 
one study also suggested that BAC can be a novel allergen, showing that between 1998-
2010 the rate of allergic patch tests to BAC had increased 111. TCS was also shown to be 
associated reproductive defects since a human study provided evidence that increased 
TCS in the urine was associated with abnormal morphology in sperm 112. This study 
supports the previous in vitro and animal studies showing TCS causing reproductive 
defects. Another study suggested that increased serum concentrations of TCS may 
influence the thyroid function of children, but not the women who were pregnant with 
them 113, again, similar to s previous in vitro and animal studies supporting TCS as an 
EDC. More human studies are needed to really investigate the effects of antimicrobials in 
human health.  
1.5 Effects of TCS on the gut microbiome and gut health 
IBD has become a serious health problem; the incidence and prevalence of IBD 
has dramatically increased throughout the world 1. Considering the growth rate of IBD 
and the lethal consequence of IBD-associated colon cancer, it is of critical importance to 
identify novel environmental risk factors to help reduce the risks posed by these diseases. 
Modulation of the gut microbiome has been implicated in a lot of diseases, and gut 
microbiota has been shown to contribute to colon inflammation 114,115. Here, we will 
discuss consumer antimicrobials as environmental factors that can increase IBD, as well 
as their effects on the gut microbiome and gut health. 
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1.5.1 Effects of TCS on animal and human gut microbiomes 
Many studies showed that TCS exposure is capable of modulating and disturbing 
the gut microbiome in various animal models. In fathead minnows exposed to TCS for 
one week, their gut microbial communities experienced a decrease in alpha diversity and 
a modulation of their composition compared with gut microbial communities in 
unexposed fish 116. The gut microbial communities of zebrafish exposed to TCS for one 
week experienced a decrease in species richness 117. Gut microbiomes of adolescent rats 
exposed to TCS were also had a reduction in the relative abundance of bacteria from the 
phylum Firmicutes and an increase in bacteria from the phylum Bacteroidetes compared 
with the gut microbiomes of unexposed rats 118. TCS exposure for 13 weeks decreased 
species richness and also significantly modulated 9 groups of bacterial families in the gut 
microbiomes of TCS-exposed mice compared with control mice 119. In other animal 
studies, TCS exposure was found to also perturb the gut microbiome in aeroallergen-
sensitized mice and BALB/c mice 110,120. Consistent with these previous studies, our 
recent study showed that a 3-week treatment of TCS via diet reduced the diversity and 
altered the composition of the gut microbiome in C57BL/6 mice 121. Altogether, these 
results show that TCS can perturb the gut microbiome in various animal models. 
In this study, the fish were exposed to low doses of TCS (0.1-1 ppb which is 
equivalent to 0.35-3.45 nM) to mimic the levels of TCS detected in the aquatic 
environment 116. The dose used in fathead minnows is quite low compared to the TCS 
levels found in humans after toothpaste use (~90-1000 nM) 59,60, yet there was still a 
potent effect on the gut microbiomes of these animals, suggesting that there may be a 
similar effect in humans. 
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Recent human studies support that routine exposure to TCS, through the use of 
TCS-containing personal care products (PCPs) or consumption of TCS-containing breast 
milk, can alter the human gut microbiomes. In one study, recent mothers who reported 
using PCPs containing TCS provided both their breast milk and their infant stool samples 
for evaluation of the infants’ gut microbiomes  64. Interestingly, the gut microbiomes of 
infants who received breast milk containing TCS had significantly lower alpha diversity 
compared with infants who received breast milk with non-detectable levels of TCS. In 
addition, the relative abundances of certain bacteria were modulated in the infants who 
were fed TCS-containing breast milk 64. Another study, recent mothers were given 
different TCS-containing PCPs that exposed individuals to TCS orally or dermally, and 
the adult and infant gut microbiomes were evaluated 65. There was a decrease in the 
diversity of mothers’ gut microbiomes and an increase in the relative abundance of 
broadly antibiotic-resistant Proteobacteria species in adults 65. However, we need to 
acknowledge that there are also inconsistent results. Some infants who consumed TCS-
containing breast milk had similar gut microbiomes to infants receiving breastmilk not 
containing TCS 65. Also, the gut microbiomes of human subjects exposed to TCS via 
PCPs for 4 months were not significantly different from unexposed human subjects 122. 
Altogether, animal studies, and some human studies, show that environmentally 
relevant concentrations of TCS has been shown to modulate the gut microbiome. 
However, these studies do not go further to discuss what the modulation of the gut 
microbiome in these animal studies could mean in terms of animal and human health. 
Modulation of the gut microbiome has been implicated in a lot of diseases including 
metabolic diseases 114. Gut microbiota has also been shown to contribute to colon 
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inflammation 115. Therefore, our study aimed to further understand the effects of TCS on 
the gut microbiome and how the gut microbiome plays a role in the pathogenesis of 
colitis and colon cancer.   
1.5.2 Effects of TCS on gut health 
Our study sought to understand how TCS could affect diseases, specifically colitis 
and colon cancer, through its modulation of the gut microbiome 121. Our recent study 
showed that exposure to 10-80 ppm TCS via diet induced colonic inflammation, 
exaggerated dextran sodium sulfate (DSS)- or Interleukin 10 (IL-10) knockout-induced 
colitis, and exacerbated the development of azoxymethane (AOM)/DSS-induced colon 
tumorigenesis in mouse models, suggesting that TCS has potential adverse effects on gut 
health 121. Gut microbiota has been shown to contribute to colon inflammation 115, so we 
evaluated the gut microbiome’s role in TCS-enhanced colitis. Compared with unexposed 
mice, TCS-exposed mice had a decrease in the alpha diversity in their gut microbiomes 
and a modulation of their gut microbial composition at phylum and genus levels 121. 
These results are consistent with the previous animal studies summarized previously 116-
119. Due to this, we wanted to see if this modulation of the gut microbiome by TCS 
played a role in the proinflammatory effects of TCS. 
Regarding the mechanisms by which TCS exposure exaggerates colonic 
inflammation and colon cancer, our study supports that the gut microbiome plays an 
essential role. Indeed, TCS exposure induces colonic inflammation in conventionally 
raised mice, but not in mice lacking a gut microbiome (germ-free mice) or mice lacking 
Toll-like receptor 4 (Tlr4-/- mice), a critical regulator of host-microbiome interactions. 
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These results support that the gut microbiome is required for the pro-inflammatory effects 
of TCS 121. Again, since substantial studies, including our current study, have shown that 
TCS has potent effects to alter gut microbiome in animals 116-119 and human subjects 64,65, 
we think that it is of critical importance to reassess the potential adverse effects of TCS 
on the gut microbiome and gut health, in order to generate science-based regulatory 
policies.  
A critical question is whether the results observed in animal models could reflect 
the responses of human exposure to TCS. The doses of TCS used in our study (10-80 
ppm in diet) are among the lowest doses used in animal experiments of TCS 121,123. Using 
LC-MS/MS, we found that after mice were exposed to 10–80 ppm TCS via diet for 3 
weeks, the concentrations of TCS and its metabolite in mouse plasma were comparable to 
the concentrations reported in the plasma of TCS-exposed human volunteers 59,60. In 
addition, we treated mice for several weeks, while humans could be exposed to TCS for 
many years. We have to point out that there are many challenges to use mouse models to 
study human exposure to consumer chemicals, and there could be fundamental 
differences in absorption, metabolism, secretion, and biological responses to TCS 
between mice and humans 123. Together, these results support that it is essential to 
evaluate the impact of TCS on gut health further. 
1.6 Significance and hypothesis 
The incidence and prevalence of IBD are dramatically increasing in the United 
States and other countries, making IBD a serious health problem 1. Emerging evidence 
supports that environmental factors are primarily responsible for the growing incidence 
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of IBD 3-5. Considering the growing incidences and potential lethal consequence of IBD-
associated colon cancer, it is of practical importance to identify novel environmental risk 
factors, in order to reduce the risks posed by IBD and associated diseases. 
Triclosan (TCS) is an antimicrobial compound incorporated into many consumer 
products, is frequently detected in the human body, and is an environmental contaminant 
in the US 8,46. Our recent study showed that exposure to low-dose TCS exaggerates 
colonic inflammation and exacerbates the development of colitis-associated colon 
tumorigenesis in mouse models, suggesting that TCS could have adverse effects on gut 
health 121. Exposure to TCS alters the gut microbiome and fails to induce colonic 
inflammation in mice lacking a gut microbiome (germ-free mice), supporting that the gut 
microbiome contributes to the pro-inflammatory effect of TCS 121. However, the 
functional roles of the gut microbiota, as well as specific gut bacteria involved, in the 
pro-inflammatory effects of TCS are unknown.  
One functional role of the gut microbiota is its ability to metabolize xenobiotics. 
Because TCS contains a phenolic structural moiety (-Ph-OH), it is highly susceptible to 
Phase II metabolizing enzymes such as glucuronyl transferase and sulfotransferase. 
Indeed, in vivo studies showed that TCS is rapidly metabolized by Phase II enzymes 124, 
leading to the formation of TCS glucuronide and TCS sulfate which are water-soluble, 
biologically inactive, and are rapidly secreted out of the body. However, TCS metabolism 
in the colon has not been characterized. Determining the metabolites of TCS in the colon, 
along with gut microbiota’s role in TCS metabolism, is important for understanding its 
pro-inflammatory effects.  
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The long-term goal of our research is to identify novel environmental risk factors 
for IBD and associated colon cancer, in order to prevent these diseases. To achieve this, 
the objective of this research is to validate the effects and mechanisms of triclosan, as 
well as other consumer antimicrobials, and the gut microbiome on IBD. We hypothesize 
that the gut microbiota is responsible for colonic metabolism of TCS, and that TCS itself, 
but not its metabolites, are responsible for its biological activity. In addition, we 
hypothesize that other consumer antimicrobials such as TCC, BAC, BET, and PCMX are 
also able to have detrimental effects on gut health.  
To test these hypotheses, we propose the following specific aims: 
Aim 1. To characterize the major metabolites of TCS in the colon, determine the 
role of the gut microbiome in TCS metabolism, and identify specific bacteria involved in 
TCS metabolism.  
Aim 2. To compare the biological effects of TCS and its metabolites. 
Aim 3. To determine the effects of other antimicrobials (TCC, BAC, BET, and 
PCMX) on gut health.  
Our research can lead to the further understanding of the effects of these 
antimicrobials on gut health, which may lead to a significant impact on regulatory 
policies of these antimicrobials. Furthermore, this information may help us understand 
more about what environmental factors play a role in IBD. 
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Figure 1.1: Chemical structures of triclosan (TCS), triclocarban (TCC), 
benzalkonium chloride (BAC), benzethonium chloride (BET), and chloroxylenol 
(PCMX). 
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CHAPTER 2 
 
METABOLIC REACTIVATION OF THE ENVIRONMENTAL TOXICANT 
TRICLOSAN BY GUT MICROBIOTA 
2.1 Introduction  
Previous research regarding the metabolism of environmental toxicants and 
pollutants has mainly focused on the metabolic processes in the mammalian host tissues. 
Indeed, substantial research has shown that once the environmental compounds enter the 
body, they are rapidly metabolized by Phase I and Phase II metabolizing enzymes, which 
are commonly expressed in various host organs, resulting in the formation of 
glucuronide- and sulfate-conjugates. These conjugates are usually water-soluble, 
biologically inactive, and are rapidly removed from the body, leading to inactivation and 
detoxification of the environmental compounds 125. Based on these findings, some 
previous studies had suggested that due to the rapid metabolism and low stability of many 
environmental compounds, exposure to low doses of these compounds is not likely to 
cause adverse effects in vivo 126-129. However, most previous research has only focused on 
the metabolic reactions in the host tissues 125, while the gut microbiota-mediated 
biotransformation is understudied 130,131.  
Emerging research supports that gut microbiota play critical roles in xenobiotic 
metabolism 130,131. The microbiota can catalyze highly unique metabolic transformations, 
such as hydrolytic (e.g. de-glucuronidation and de-sulfatation), reductive (e.g. C=C or 
N=N bond reduction), functional group transfer (e.g. methyl or acetyl transfer), and 
radical-mediated reactions 131. Many of these metabolic reactions are distinct from 
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reactions of the host enzymes, resulting in colonic accumulation of microbiota-derived 
metabolites which could have unique activities and toxicities 131. These studies suggest 
that compared with other organs, the gut tissue could have a completely different profile 
of xenobiotic metabolism due to the presence of gut bacteria, resulting in potential gut-
specific toxicology. However, to date, the metabolism of environmental toxicants and 
pollutants in the gut tissue and the roles of gut microbiota involved are mostly unknown. 
Triclosan (TCS) is a high-volume chemical used as an antimicrobial ingredient in 
more than 2,000 consumer products: every year, several million pounds of TCS are used 
in the United States 8. Due to its widespread application and persistence, it has caused 
pollution ubiquitously in the environment and is frequently detected in the human 
population, raising concerns about its impacts on the environment and human health 8. 
Our recent research shows that exposure to TCS, at doses relevant to human exposure, 
enhances basal colonic inflammation, increases the severity of inflammatory bowel 
disease (IBD), and exaggerates IBD-associated colon tumorigenesis in mice 121. The 
adverse effects of TCS require the presence of gut microbiota since TCS exposure fails to 
promote colonic inflammation in germ-free mice 121. However, the functional roles of the 
gut microbiota involved are unknown. In this study, we used liquid chromatography-
tandem mass spectrometry (LC-MS/MS) to profile TCS metabolism in mouse models, in 
vitro culture of gut bacteria, and human subjects, to study the functional roles of gut 
microbiota in the gut metabolism of TCS.  
  
 
20 
2.2 Materials and Methods 
2.2.1 Chemicals 
Triclosan (TCS, 99% purity) was purchased from Alfa Aesar (Haverhill, MA). 
TCS glucuronide (95% purity) and TCS sulfate (95% purity) were purchased from 
Toronto Research Chemicals (Toronto, ON, Canada). 
2.2.2 DNA extraction 
DNA was extracted from mouse fecal samples and human stool using QIAmp 
DNA Stool Mini Kit (Qiagen, Valencia, CA) following instructions from the 
manufacturer with an additional bead-beating step. The quantity of the extracted DNA 
was measured using a NanoDrop Spectrophotometer (Thermo Fisher Scientific), and the 
quality was verified using gel electrophoresis. The DNA was then subjected to further 
analysis. 
2.2.3 Real-Time PCR analysis of 16S rRNA gene and strain-specific bacteria 
primers 
DNA extracted from mouse fecal samples were subjected to qPCR analysis 
using a DNA Engine Opticon system (Bio-Rad Laboratories, Hercules, CA). 20 µL 
PCR reactions were made using the Maxima SYBR_green Master Mix (Thermo Fisher 
Scientific), and DNA was normalized to 5 ng/µL per reaction. The 16S rRNA primers 
and strain-specific bacteria primers are listed in Table 2.1. 
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2.2.4 Isolation of bacteria from mouse tissues and human stool samples 
Mouse tissues (small intestine, cecum, colon, and feces) were harvested from 
mice, and human stool samples were collected. The tissues and stool were dissolved in 
sterile PBS with 0.05% L-cysteine, then centrifuged at 900xg for 5 min. The 
supernatant containing culturable bacteria was then fermented at 37 oC in MRS broth 
in an anaerobic cabinet (Whitley A35 anaerobic work station, Don Whitley Scientific) 
under an atmosphere of 85% N2, 10% CO2, and 5% H2. In addition, the remaining 
supernatant (~0.6 mL) containing culturable bacteria was then mixed with sterile 50% 
glycerol (0.3 mL) and stored at -80 oC as stock for future experiments. 
2.2.5 In vitro fermentation of bacteria 
The bacterial strains (Lactobacillus strains: L. brevis 14869, L. Sakei 11146, L. 
reuteri DSM 20016, L. rhamnosus ATCC 7469, L. gasseri 33323, L. reuteri DSM 
20053; Bifidobacterium strains: B. animalis subsp. animalis 25527, B. breve 15700, B. 
bifidum 29521, B. infantis 15697, B. longum 15707, B. pseudocatenulatum) were 
obtained from the Agriculture Research Service Culture Collection (NRRL). Strains 
and isolated bacteria from mouse tissues and human stool samples were fermented at 
37 oC in MRS broth in an anaerobic cabinet (Whitley A35 anaerobic work station, Don 
Whitley Scientific) under an atmosphere of 85% N2, 10% CO2, and 5% H2. When the 
OD600 reached 0.5, bacteria were then inoculated 1:10 into MRS broth containing 
either DMSO vehicle, 20 µM TCS, or 20 µM TCS glucuronide. After 48 h, the samples 
were collected and stored in -80 oC for further analysis. 
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2.2.6 Growth curves of pure bacteria 
Pure strains of bacteria (listed above) were fermented at 37 oC in MRS broth in 
an anaerobic cabinet (Whitley A35 anaerobic work station, Don Whitley Scientific) 
under an atmosphere of 85% N2, 10% CO2, and 5% H2. When the OD600 reached 0.5, 
bacteria were inoculated 1:100 into MRS broth containing either DMSO vehicle, TCS 
(0.1-1 µM), or TCS glucuronide (20 µM) in a 96-well plate. The plate was entered into a 
plate reader, and the OD600 was measured from 0-30 h. 
2.2.7 Human urine and stool collection 
Human urine and stool samples from a previous study 122 were utilized 
(schematic of human urine and stool sample collection is shown in Figure 2.9A). 
Briefly, healthy human volunteers from Stanford University were given personal care 
products either containing or not containing TCS. Urine and stool samples were then 
collected from the volunteers before and 1-4 months after using the personal care 
products. The study was approved by the Institutional Review Board of Stanford 
University (ClinicalTrials.gov identifier NCT01509976). 
2.2.8 Extraction of TCS metabolites 
Mouse tissues and human stool were placed in homogenizer tubes with beads 
and 1 mL methanol, then homogenized using a bead-disruptor (OMNI International, 
Kennesaw, GA). Samples were centrifuged at 10,000 rpm at room temperature for 3 
min. The supernatant was collected and then centrifuged again at 14,000 rpm at room 
temperature for 5 min. 500 µL of the supernatant was then collected and vacuum- 
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centrifuged to dryness. For bacterial broth (50 µL) and human urine (100 µL), each 
sample was combined with 1 mL methanol and placed on ice. After 10 min on ice, 
samples were centrifuged at 14,000 rpm at room temperature for 5 min. 500 µL of the 
supernatant was then collected and vacuum- centrifuged to dryness. The extracts were 
re-dissolved in methanol with amount that was proportional to sample weights or 
volumes, then centrifugated (14,000 rpm, 15 min, 4℃) before the LC-MS/MS analysis. 
2.2.9 Detection of TCS and TCS metabolites by LC-MS/MS 
TCS, TCS glucuronide, and TCS sulfate in the samples were quantified using a 
Thermo Scientific Dionex Ultimate 3000 ultrahigh performance liquid chromatography 
(UHPLC) system coupled with a TSQ Quantiva Triple Quadrupole Mass Spectrometer. 
ACQUITY UPLC C18 column (1.7 μm particles, 2.1 mm × 100 mm, Waters) was used 
for chromatographic separation. Data acquisition was performed by multiple reaction 
monitoring (MRM) mode. 
Hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS sulfate were 
monitored by a Thermo Scientific Dionex Ultimate 3000 UHPLC system coupled with 
an Orbitrap Fusion Tribrid Mass Spectrometer. Chromatographic separation was 
achieved on an ACQUITY UPLC HSS T3 column (1.7 μm particles, 2.1 mm × 100 
mm, Waters). Targeted MS2 mode was used for metabolite identification. Details of 
the instrumental methods are provided in Table 2.2-3 The data were analyzed using 
Xcalibur software (version 4.1, Thermo Fisher Scientific). 
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2.2.10 Cell culture and treatment with TCS, TCS glucuronide, and TCS sulfate 
MC38 mouse colon cancer cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and incubated at 
37 oC under an atmosphere of 5% CO2. MC38 cells were seeded at 20% confluency 
and left to settle overnight. Cells were then treated with either 1 µM TCS, TCS 
glucuronide, TCS sulfate, or vehicle (DMSO). After 48 h, cells were harvested for RT-
qPCR analysis, and cell medium was collected for ELISA analysis. 
2.2.11 Reverse-Transcriptase-qPCR of inflammatory biomarkers 
Total RNA was isolated from them using Trizol reagent (Ambion) according to 
the manufacturer’s instruction. RNA was reverse transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystem) according to the 
manufacturer’s instructions. 20 µL PCR reactions were prepared using the Maxima 
SYBR_green Master Mix (Thermo Fisher Scientific), and qPCR was carried out using 
a DNA Engine Opticon system (Bio-Rad Laboratories). Mouse-specific primer 
sequences (Thermo Fisher Scientific) used to detect inflammatory biomarkers are listed 
in Table 2.1. Gapdh expression was used as an internal control. 
2.2.12 ELISA of inflammatory biomarkers 
Cell medium from MC38 colon cancer cells treated with either 1 µM TCS, TCS 
glucuronide, TCS sulfate, or vehicle (DMSO) for 48 h was collected, and 30 µL from 
each sample was used. Cytokine concentrations in the medium were determined using 
the CBA Mouse Inflammation Kit (BD Sciences) according to the manufacturer’s 
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instructions. Data were acquired using a BD LSR Fortessa flow cytometer (BD 
Biosciences) and analyzed using FlowJo software (Treestar). 
2.2.13 In vitro fermentation of human stool bacteria for 16S rRNA sequencing 
Human fecal samples were collected from 8 individuals (4 male and 4 female, 
age = 25-30 years, Asian, healthy, without pre-, pro-, or anti-biotics for at least 3 
months). Bacteria from the samples were isolated and cultured at 37 oC in Gifu 
Anaerobic (GAM) broth (HIMedia Laboratories, West Chester, PA), in an anaerobic 
cabinet (Whitley A35 anaerobic workstation, Don Whitley Scientific, UK) under an 
atmosphere of 85% N2, 10% CO2, and 5% H2. Bacteria were inoculated 1:10 (v/v) 
into GAM broth containing TCS (0.1 and 1 µM) or 0.1% DMSO vehicle and incubated 
at 37 oC in the anaerobic cabinet for 48 h. After incubation, bacteria were collected for 
DNA extraction and 16S rRNA sequencing. 
2.2.14 Microbial phylogenetic profiling by 16S rRNA sequencing 
All PCR reactions were performed in a 96-well plate on a T100TM thermal 
cycler (Bio-Rad) with 2X KAPA HiFi Hotstart ReadyMix (KAPA Biosystem, 
Wilmington, MA). First, PCR was performed to amplify DNA of the bacterial 
community with primers (see Table 2.1) that bound the V3-4 regions of the 16S rRNA 
gene. The primers also incorporated the Illumina overhang adaptor. After purification 
with AMPure XP beads (Beckman Coulter, Danvers, MA), limited cycle PCR was 
performed using the Nextera XT Index Kit (Illumina, San Diego, CA) to attach dual 
indices and Illumina sequencing adapters. After another purification with AMPure XP 
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beads, the quantity of the purified PCR products was measured by Qubit dsDNA BR 
Assay kit (Life Technology, Carlsbad, CA) and the amplicon quality was estimated by 
ScreenTape Assay on Tape Station 2200 (Agilent Technologies, Santa 
Clara, CA). Samples were then pooled in equimolar amount and pair-end 2*300bp 
sequencing was performed using a MiSeq reagent kit V3 (5% PhiX) (Illumina, San 
Diego, CA) on Illumina MiSeq platform. Sequencing was performed at Genomics 
Resource Laboratory, University of Massachusetts Amherst. 
Sequencing data was processed using the QIIMETM software pipeline v1.9.1 
132. Generally, the high- quality sequence data (quality value ≥ 30) was demultiplexed. 
Sequences were then clustered into operational taxonomic unites (OTUs) using the 
open reference OTU picking against Greengenes bacterial 16S rRNA database (13_8 
release) with 97% similarity threshold. The α-diversity (the diversity within sample 
community species richness) was determined with ten iterations at a maximal sequence 
depth where all samples could be included. 
2.2.15 Data and Statistical Analyses 
Data are expressed as mean ± SEM. The statistical comparison of two groups 
was analyzed using Student’s t-test. The statistical comparison of three or more groups 
was analyzed using one-way ANOVA. The analysis of TCS metabolites in colon 
digesta of mice (Figure 2.2) according to antibiotic treatment and TCS treatment was 
performed using two-way ANOVA. The statistical analyses were performed using SAS 
statistical software and SigmaPlot. P < 0.05 was considered statistically significant. 
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2.3 Results 
2.3.1 Profiles of TCS metabolites in mouse tissues 
To our knowledge, detailed profiling of TCS metabolism in animal tissues has not 
been attempted. To this end, we treated mice with TCS via diet for 4 weeks, then used 
LC-MS/MS to profile TCS metabolites in various tissues. In agreement with previous 
studies 123, we found that, in most organs, such as the liver, bile, heart, and small intestine 
(mucosa and digesta), the dominant TCS metabolites were its glucuronide- and sulfate-
conjugates (Figure 2.1). However, in the digesta of the cecum and colon tissues, the 
dominant metabolite was free-form TCS, with very low concentrations of the conjugates. 
Indeed, the relative percentage of free-form TCS, TCS glucuronide, and TCS sulfate in 
the colon digesta were 99.1 : 0.69 : 0.23 (Figure 2.1), illustrating a different profile of 
TCS metabolism. 
 
2.3.2 Role of gut microbiota in the colonic metabolism of TCS in mice 
Compared with other organs such as the liver, a major difference of the colon 
tissue is that the colon harbors a large number of gut bacteria 130. To determine whether 
gut microbiota mediate the unique profile of TCS metabolism in the colon digesta, we 
tested whether antibiotic cocktail-mediated suppression of gut microbiota alters TCS 
metabolism in the colon digesta (see the scheme of the animal experiment in Figure 
2.2A). We used an antibiotic cocktail from previous studies 133,134 and found that 
treatment with the cocktail caused a dramatic reduction of fecal bacteria, as assessed by 
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qPCR analysis of the 16S rRNA gene (Figure 2.3), validating the depleting effects of the 
cocktail on gut microbiota.  
We found that treatment with the antibiotic cocktail reduced the concentration of 
free-form TCS (~50% reduction), while enhancing the concentration of TCS glucuronide 
(~6-fold increase) and TCS sulfate (~5-fold increase) in the colon digesta (Figure 2.2B), 
see complete LC-MS/MS results in Table 2.4). Two-way ANOVA analysis showed that 
there was a significant interaction between antibiotic cocktail treatment (antibiotic 
cocktail versus water) and TCS treatment (TCS versus vehicle) on both free-form TCS (P 
< 0.001) and TCS-conjugates (P = 0.009). These results support that gut microbiota 
mediate the conversion of TCS glucuronide and/or TCS sulfate conjugates to free-form 
TCS, contributing to the colonic metabolism of TCS. 
Using MS/MS-based fragmentation analysis, we also identified some novel 
metabolites, including hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS 
sulfate, in the colon digesta (see mass spectrum of these compounds in Figure 2.4), and 
found that the profiles of these metabolites were also dependent on gut microbiota. 
Consistent with our results above, the antibiotic cocktail treatment reduced the 
concentration of free-form hydroxyl-TCS while increasing the concentration of hydroxyl-
TCS glucuronide and hydroxyl-TCS sulfate in the colon digesta (Figure 2.2C-E, see 
complete LC-MS/MS results in Table 2.5). Two-way ANOVA analysis also showed that 
there was a significant interaction between antibiotic cocktail treatment and TCS 
treatment on these novel metabolites (P < 0.001 for all three metabolites). These results 
further support the roles of gut microbiota in colonic metabolism of TCS. 
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2.3.3 Effects of gut bacteria on the metabolism of TCS in vitro 
To further validate the roles of gut microbiota in TCS metabolism, we cultured 
gut bacteria under anaerobic conditions and studied their effects on TCS metabolism in 
vitro. Our results above support that gut microbiota convert TCS glucuronide to free-
form TCS in vivo (Figure 2.2), and we tested whether gut microbiota can directly catalyze 
this reaction in vitro (see the scheme of the experiment in Figure 2.5A). With the 
presence of gut microbiota from mice feces and human stool, TCS glucuronide was 
converted to free-form TCS, while this reaction was not observed without the presence of 
the bacteria (Figure 2.5B). These results support that the gut microbiota can catalyze the 
de-glucuronidation reaction in vitro.  
To explore the specific gut bacteria involved, we cultured pure bacteria strains 
and tested their effects on TCS metabolism. Out of 12 strains, we found that 3 strains, 
including Lactobacillus brevis, L. rhamnosus, and Bifidobacterium breve, were capable 
of converting TCS glucuronide to free-form TCS in vitro (Figure 2.5C). Some strains, 
such as L. reuteri (DSM 20053 and DSM 20016) and B. longum, showed no effect to 
metabolize TCS glucuronide in vitro (Figure 2.5C). To validate that the lack of metabolic 
activity was not due to suppressed bacterial growth, we tested the effects of TCS 
glucuronide on bacterial growth and found that TCS glucuronide had no effect on 
bacterial growth (Figure 2.6).  
To better understand the interactions between TCS and TCS-metabolizing 
bacteria (e.g. L. brevis, L. rhamnosus, and B. breve), we tested the effect of free-form 
TCS on the growth of these bacterial strains. Compared with vehicle (DMSO), treatment 
with TCS (concentration = 0.1-1 µM) did not affect bacterial growth in vitro (Figure 2.7). 
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Next, we tested whether TCS exposure could change the abundance of these strains in 
mouse gut microbiota. We used strain-specific primers 135,136 to perform qPCR analyses 
and found that treatment with TCS (80 ppm in diet) for 4 weeks appeared to increase, but 
not significantly, the relative abundance of these bacteria in mouse fecal microbiota 
(Figure 2.8). 
Besides the de-glucuronidation reaction, we also tested whether gut bacteria can 
catalyze the conversion of TCS to hydroxyl-TCS. We incubated TCS with gut bacteria 
from the small intestine, cecum, colon, and feces from the mice, as well as gut bacteria 
from human stool. LC-MS/MS analysis showed no formation of hydroxyl-TCS (Table 
2.6). This result suggests that at least the culturable gut bacteria cannot convert TCS to 
hydroxyl-TCS in vitro.  
 
2.3.4 Profiles of TCS metabolites in human subjects 
We analyzed the profiles of TCS metabolites in the urine and stool of TCS-
exposed human subjects. To this end, we utilized human samples from a previous study 
(ClinicalTrials.gov identifier NCT01509976), in which the human subjects were exposed 
to TCS by using personal care products for up to 4 months (see scheme of experiment in 
Figure 2.9A) 122.  
LC-MS/MS showed that the dominant metabolites in human urine are the 
conjugates: after 4 months of exposure, the relative percentages of TCS conjugates (a 
combination of TCS glucuronide and TCS sulfate) and free-form TCS in the urine was 
~99.5 : 0.5 (Figure 2.9B, see complete LC-MS/MS results in Table 2.7-8). However, in 
the stool, the dominant metabolite is free-form TCS: after 4 months of exposure, the 
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relative percentages of TCS conjugates and free-form TCS in the feces was ~1.7 : 98.3  
(Figure 2.9C, see complete LC-MS/MS results in Table 2.9-10). These results are in 
agreement with the mouse study as described above, which showed that colon digesta (or 
feces) versus other tissues have distinct profiles of TCS metabolites.  
 
2.3.5 Effects of TCS and its conjugates on inflammation in vitro  
Our results above support that gut microbiota convert TCS conjugates to free-
form TCS in the colon. To explore the biological significance of the microbiota-mediated 
metabolism, we studied the comparative effects of TCS conjugates (TCS glucuronide and 
TCS sulfate) versus free-form TCS. We treated MC38 colon cancer cells with 1 µM of 
each compound and studied the inflammatory responses. We determined the 
concentration using our results above which showed that the concentration of free-form 
TCS in the stool of TCS-exposed human subjects was up to ~1100 pmol/g (calculated to 
be ~ 1 µM, see Figure 2.9C and Table 2.9). Using qRT-PCR analysis, we found that 
treatment with TCS increased the gene expression of pro-inflammatory cytokines (Il6, 
Ifng, Il1b, and Mcp1) in MC38 colon cancer cells, while TCS glucuronide and TCS 
sulfate had no such effects (Figure 2.10A). Furthermore, ELISA analysis showed that 
treatment with TCS, but not the conjugates, increased concentrations of pro-inflammatory 
cytokines (IL-6, IFN-γ, and TNF-α) and reduced an anti-inflammatory cytokine IL-10 in 
the medium of MC38 cells (Figure 2.10B). Together, these results suggest that the gut 
microbiota convert TCS conjugates, which are biologically inactive, to generate free-
form TCS, which has potent and direct pro-inflammatory effects, supporting the 
biological significance of the microbiota-mediated metabolism.  
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After demonstrating that free-form TCS had direct pro-inflammatory effects, we 
further studied the direct effect of free-form TCS on gut microbiota in vitro. Previous 
studies showed that exposure to TCS altered gut microbiota in animals and humans 65,116-
119,121; however, it remains unknown whether TCS has a direct effect on gut microbiota. 
We cultured human fecal microbiota derived from 8 healthy volunteers, treated with TCS 
(concentration = 10 nM, which represents the low concentration of free-form TCS in the 
stool of TCS-exposed human subjects, see Figure 2.9C and Table 2.9) or vehicle 
(DMSO) under anaerobic conditions, then analyzed gut microbiota using 16S rRNA 
sequencing (see scheme of experiment in Figure 2.11A). At this low concentration, TCS 
treatment had no significant effect on the diversity of the microbiota (Figure 2.11B). 
Regarding microbiota composition, TCS treatment altered bacterial abundance at both the 
phylum and genus levels (Figure 2.11C-D and Figure 2.12). Notably, TCS treatment 
increased the relative abundance of Proteobacteria, which is shown to be increased in 
IBD patients and is positively associated with the pathogenesis of IBD (Figure 2.11D) 137. 
Together, these results support that free-form TCS has a potent and direct effect of 
altering gut microbiota, resulting in a potential pro-inflammatory phenotype. 
2.4 Discussion   
Previous research regarding the metabolism of TCS, as well as many other 
environmental compounds, has only focused on the metabolic processes in mammalian 
host tissues (e.g. liver), while the gut microbiota-mediated metabolism is understudied. 
Notably, previous studies showed that after TCS enters the body, it is rapidly metabolized 
by phase II detoxification enzymes, resulting in the formation of TCS glucuronide and 
  
 
33 
TCS sulfate, which are water-soluble, biologically inactive, and are quickly removed 
from the body 123. Here, our central finding is that gut microbiota catalyzes unique 
metabolic conversions of TCS, resulting in colonic re-generation of free-form TCS 
species which has potent and direct effects on both colon epithelial cells and gut bacteria 
to induce a pro-inflammatory phenotype (see proposed model in Figure 2.13). This leads 
to the accumulation of biologically active free-form TCS in the gut, and this could lead to 
gut-specific toxic effects. These results highlight the critical importance of gut microbiota 
in the metabolism and bioactivity of TCS. In addition, these results suggest that, besides 
TCS, many other environmental chemicals could also be metabolically re-activated in the 
gut by the actions of gut microbiota, resulting in the accumulation of microbiota-derived 
toxic metabolites in the colon and leading to gut-specific toxicity.  
Our results are in agreement with previous studies which showed that β-
glucuronidase-expressing gut bacteria could catalyze de-glucuronidation reactions 138.  
We identified three strains of bacteria, including L. brevis, L. rhamnosus, and B. breve, 
that were capable of converting TCS glucuronide to free-form TCS in vitro. This is 
consistent with previous studies, which showed that these strains have expression of β-
glucuronidase 139-141. Interestingly, we found that some β-glucuronidase-expressing gut 
bacteria, such as B. bifidum and L. gasseri 142,143, can’t convert TCS glucuronide to free-
form TCS, suggesting that only specific β-glucuronidase isoforms recognize TCS 
glucuronide as a substrate. It is feasible that, upon TCS exposure, individuals with 
different profiles of gut bacteria or activities of gut metabolizing enzymes could have 
varied colonic metabolism of TCS, resulting in inter-individual variations in biological 
responses to TCS exposure. Notably, previous studies showed that the fecal β-
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glucuronidase activity was significantly increased in colon cancer patients (~12-fold 
increase of the enzymatic activity compared with healthy controls) 144, suggesting an 
enhanced metabolic re-activation of TCS, which has colon cancer-enhancing effects 121, 
in colon cancer patients. Elucidation of the roles of gut bacteria in the metabolism and 
bioactivity of TCS could help to design better human studies to clarify the health impacts 
of TCS.  
Our results support that due to the unique metabolic reactions catalyzed by gut 
microbiota (e.g. de-glucuronidation reaction), microbiota-derived toxic metabolites (e.g. 
the free-form parent compound) could be accumulated in the gut tissues, resulting in gut-
specific toxicity. This suggests that during an evaluation of the toxicology of 
environmental toxicants and pollutants, it is of critical importance to study the 
metabolism and toxicity in the gut tissues. Indeed, our recent study showed that TCS 
exposure, at low doses, enhances basal colonic inflammation, increases the severity of 
IBD, and exaggerates colon tumorigenesis in mice 121. Previous studies have shown that 
TCS exposure could also cause adverse effects in other tissues such as liver 145; however, 
it is noteworthy that the reported TCS doses to cause liver toxicity are higher than the 
doses needed to exacerbate gut toxicity 121,145. This could be, at least in part, caused by 
the different fate of TCS in the liver and gut tissues: in the liver, the dominant 
metabolites are glucuronide- and sulfate-conjugates, which are usually biologically 
inactive; in the gut, the dominant metabolites are free-form TCS species, which have 
direct and potent effects on both colon epithelial cells and gut bacteria to induce a pro-
inflammatory phenotype. Indeed, in our study, after a 4-week exposure to TCS in mice, 
the average concentration of free-form TCS (the putative biologically active compound) 
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was ~7.3 pmol/mg tissue in the liver versus ~282.8 pmol/g tissue in the colon digesta, 
suggesting an accumulation of toxic compounds in the colon which could result in colon-
specific toxicology. Besides TCS, many other environmental toxicants and pollutants 
could also be metabolically re-activated by gut microbiota and result in gut-specific 
toxicity, highlighting the critical importance of evaluating the impacts of environmental 
exposure on gut health.  
In summary, our results, using LC-MS/MS profiling in mouse models and human 
subjects, as well as in vitro culture of gut bacteria, support that gut bacteria mediates 
unique metabolic reactions of environmental toxicant TCS in the gut, resulting in 
metabolic re-activation of TCS and potentially gut-specific toxicity. Based on our study, 
it is of critical importance to better understand the toxicology of environmental toxicants 
and pollutants in the gut tissues.  
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Table 2.1. Sequences of primers for qPCR analysis. 
 
Gene Forward primer sequence Reverse primer sequence 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Ifng ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC 
Il1b GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Mcp1 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
16S rRNA CCTACGGGTGGCTGCAG GACTACTAGGGTATCTAATCC 
B. breve ATGGCAAAACCGGGCTGAA GCGGATGAGAGGTGGG 
L. brevis CTTGCACTGATTTTAACA GGGCGGTGTGTACAAGGC 
Primers for sequencing 
16S rRNA TCGTCGGCAGCGTCAGATGTGTAT 
AAGAGACAGCCTACGGGNGGCWGC
AG 
GTCTCGTGGGCTCGGAGATGTGTA
TAAGAGACAGGACTACHVGGGTAT
CTAATCC 
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Table 2.2. Instrumental method for the quantification of TCS, TCS glucuronide, 
and TCS sulfate. 
 
Instrument 
Thermo Scientific Dionex Ultimate 3000 UHPLC system coupled with 
a TSQ Quantiva Triple Quadrupole Mass Spectrometer 
Analytical column 
and temperature 
ACQUITY UPLC C18 column (1.7 μm particles, 2.1 mm × 100 mm, 
Waters), 30 °C 
Mobile phases A. Acetonitrile B. Ammonium acetate (2 mM) in water 
 
 
 
 
 
Gradient profile 
Time (min) 
0.0 
1.0 
2.5 
5.0 
5.5 
6.5 
7.0 
9.0 
Percentage A (%) 
15 
15 
80 
80 
100 
100 
15 
15 
Flow rate (mL/min) 
0.30 
0.30 
0.30 
0.30 
0.30 
0.30 
0.30 
0.30 
Injection volume 10 μL 
MS scan mode Multiple reaction monitoring (MRM) 
 
 
 
 
Monitored MRM 
transitions 
Analytes MRM transition (m/z) Collision Energy (eV) 
TCS 
286.89 → 35.22 
288.89 → 35.22 
16 
16 
13C12-TCS 
299.00 → 35.22 
301.00 → 35.22 
16 
16 
TCS glucuronide 
463.00 → 175.00 
463.00 → 287.00 
15 
15 
TCS sulfate 
366.89 → 286.89 
368.89 → 288.89 
15 
15 
 
 
 
MS/MS parameters 
Electrospray ionization (ESI): negative ionization mode; 
Capillary voltage (kV) = 2.5; 
Sheath gas (arbitrary units) = 40; 
Auxiliary gas (arbitrary units) = 10; 
Ion transfer tube temperature (°C) = 350; 
Vaporizer temperature (°C) = 300. 
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Table 2.3. Instrumental method for the identification of hydroxyl-TCS, 
hydroxyl-TCS glucuronide, and hydroxyl-TCS sulfate. 
 
 
Instrument 
Thermo Scientific Dionex Ultimate 3000 UHPLC system coupled 
with an Orbitrap Fusion Tribrid Mass Spectrometer (UHPLC–Orbitrap 
Fusion MS) 
Analytical column 
and temperature 
ACQUITY UPLC HSS T3 column (1.7 μm particles, 2.1 mm × 100 
mm, Waters), 30 °C 
Mobile phases A. Methanol B. Ammonium acetate (5 mM) in water 
 
 
 
 
Gradient profile 
Time (min) 
0.0 
1.0 
6.0 
9.0 
10.0 
12.0 
12.5 
15.0 
Percentage A (%) Flow rate (mL/min) 
10  0.30 
10 0.30 
80 0.30 
80 0.30 
100 0.30 
100 0.30 
10 0.30 
10 0.30 
Injection volume 10 μL 
MS scan mode Targeted MS2 
 
 
Ion transitions for 
metabolite 
identification 
Analytes Parent ion (m/z) Product ion (m/z) 
hydroxyl-TCS 302.9388 266.9627, 160.9561, 156.9703 
hydroxyl-TCS 
glucuronide 478.9709 
302.9388, 266.9627, 175.0254, 
160.9561, 156.9703, 113.0239 
hydroxyl-TCS 
sulfate 382.8956 
302.9388, 266.9627, 160.9561, 
156.0703, 79.9574 
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MS/MS parameters 
Global MS parameters 
Spray voltage (kV) = 3.0; 
Sheath gas (arbitrary units) = 50; 
Auxiliary gas (arbitrary units) = 15; 
Ion transfer tube temperature (°C) = 285; 
Vaporizer temperature (°C) = 300. 
Targeted MS2 parameters 
Isolation widow (m/z) = 0.8; 
Activation type: high-energy collision dissociation (HCD); 
HCD collision energy (%) = 25; 
Orbitrap resolution = 30000; 
Scan range (m/z) = 50–600; 
Automated gain control (AGC) target = 5 × 104; 
Maximum injection time (ms) = 100; 
Polarity: Negative. 
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Table 2.4 Concentrations of free-form TCS, TCS glucuronide, and TCS sulfate in mouse tissues after treatment. 
See the scheme of animal experiment in Figure 2.2A. Statistical significance of the interaction effect between antibiotics treatment 
(antibiotics versus water) and TCS treatment (TCS versus vehicle) on TCS metabolites was determined using two-way ANOVA. 
 
 Treatment  
 
Vehicle 
 
Antibiotics 
 
TCS 
TCS + 
Antibiotics 
 
TCS metabolites 
(pmol/mg of tissue) 
 
Mean 
 
SEM 
 
Mean 
 
SEM 
 
Mean 
 
SEM 
 
Mean 
 
SEM 
Interaction 
P-value 
 
colon 
digesta 
TCS 
TCS glucuronide 
TCS sulfate 
0.59 
0.00 
0.00 
0.06 
0.00 
0.00 
0.35 
0.01 
0.01 
0.08 
0.00 
0.00 
288.27 
0.79 
1.74 
19.69 
0.30 
0.24 
147.15 
10.87 
12.94 
6.91 
4.76 
0.72 
< 0.001 
0.155 
< 0.001 
 
colon 
mucosa 
TCS 
TCS glucuronide 
TCS sulfate 
0.19 
0.00 
0.06 
0.03 
0.00 
0.02 
0.12 
0.01 
0.24 
0.01 
0.00 
0.08 
7.02 
0.19 
7.85 
0.67 
0.15 
0.60 
10.80 
6.29 
20.73 
0.78 
0.73 
1.03 
0.015 
< 0.001 
< 0.001 
small TCS 0.26 0.06 0.19 0.03 33.39 3.79 30.77 1.20 0.660 
intestine 
digesta 
TCS glucuronide 
TCS sulfate 
0.04 
0.05 
0.01 
0.03 
0.03 
0.01 
0.00 
0.00 
50.07 
6.97 
7.78 
0.61 
91.48 
9.07 
5.89 
0.20 
0.007 
0.030 
small TCS 0.37 0.06 0.36 0.09 34.64 4.62 38.53 3.27 0.636 
intestine 
mucosa 
TCS glucuronide 
TCS sulfate 
0.02 
0.11 
0.00 
0.02 
0.02 
0.02 
0.00 
0.00 
36.38 
8.35 
5.73 
0.72 
58.75 
13.68 
5.55 
0.42 
0.063 
< 0.001 
 TCS 0.04 0.00 0.04 0.00 7.25 0.68 12.01 0.72 0.003 
liver TCS glucuronide 0.01 0.00 0.01 0.00 1.41 0.21 4.89 0.46 < 0.001 
 TCS sulfate 0.04 0.01 0.09 0.01 28.01 2.46 43.65 3.06 0.011 
 TCS 3.09 0.48 1.88 0.40 26.74 3.43 33.09 3.49 0.294 
 41 
 
bile TCS glucuronide 0.05 0.01 0.05 0.01 142.27 22.13 276.15 35.60 0.036 
 TCS sulfate 0.13 0.03 0.05 0.01 69.40 5.26 105.20 6.41 0.006 
 TCS 0.07 0.01 0.09 0.01 0.90 0.10 0.66 0.06 0.137 
heart TCS glucuronide 0.00 0.00 0.01 0.01 1.23 0.15 2.14 0.37 0.122 
 TCS sulfate 0.01 0.00 0.27 0.18 8.79 0.52 11.83 0.37 0.006 
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Table 2.5. Peak areas of Hydroxyl-TCS, Hydroxyl-TCS glucuronide, and Hydroxyl-TCS sulfate in mouse tissues after 
treatment.  
See the scheme of animal experiment in Figure 2.2A). Statistical significance of the interaction effect between antibiotics treatment 
(antibiotics versus water) and treatment (TCS versus vehicle) on Hydroxyl-TCS metabolites was determined using two-way ANOVA. 
 
 Treatment  
Vehicle Antibiotics TCS TCS + Antibiotics 
 Hydroxyl-TCS 
metabolites (Peak 
area/mg of tissue) 
 
Mean 
 
SEM 
 
Mean 
 
SEM 
 
Mean 
 
SEM 
 
Mean 
 
SEM Interaction P-value 
 
colon 
digesta 
Hydroxyl-TCS 
Hydroxyl-TCS glucuronide 
Hydroxyl-TCS sulfate 
24967 
4009 
21042 
11521 
615 
9132 
1086 
7623 
24517 
809 
2358 
7872 
31197734 
5240 
10358930 
2000424 
931 
1906931 
3979604 
1693280 
36357272 
611500 
203969 
3841162 
< 0.001 
< 0.001 
< 0.001 
 
colon 
mucosa 
Hydroxyl-TCS 
Hydroxyl-TCS glucuronide 
Hydroxyl-TCS sulfate 
1246 
2064 
168897 
520 
1096 
48036 
783 
11146 
76284 
503 
2014 
10974 
969808 
11665 
4478284 
120281 
3403 
659995 
722270 
1117236 
22891374 
86344 
202715 
2897998 
0.256 
< 0.001 
< 0.001 
small Hydroxyl-TCS 3193 1736 5087 2435 887549 157038 133173 10319 0.003 
intestine Hydroxyl-TCS glucuronide 43482 7221 25840 12503 1857592 336104 820610 60299 0.048 
digesta Hydroxyl-TCS sulfate 27285 9900 45878 7277 17836642 2684111 25807127 929018 0.063 
small Hydroxyl-TCS 3602 2070 2294 586 534201 140727 151013 29716 0.077 
intestine Hydroxyl-TCS glucuronide 7706 1666 8429 2928 669202 110354 158949 30356 0.005 
mucosa Hydroxyl-TCS sulfate 30006 10757 20404 4350 11456388 1919544 19445667 1993610 0.055 
 Hydroxyl-TCS 1699 1292 4712 1749 113643 31205 87821 10827 0.550 
liver Hydroxyl-TCS glucuronide 8150 2117 9799 3547 167420 48614 28723 3557 0.056 
 Hydroxyl-TCS sulfate 5311 1241 5555 484 2460621 446963 4353406 457273 0.050 
 Hydroxyl-TCS 34884 15102 31577 22358 347869 49864 89741 22215 0.004 
 43 
 
bile Hydroxyl-TCS glucuronide 119330 40916 145415 44422 6850477 1635666 1431632 211132 0.030 
 Hydroxyl-TCS sulfate 111634 40925 53800 20338 40694806 1599612 56083680 2120354 < 0.001 
 Hydroxyl-TCS 0 0 0 0 0 0 0 0 1.000 
heart Hydroxyl-TCS glucuronide 0 0 0 0 0 0 0 0 1.000 
 Hydroxyl-TCS sulfate 26081 5826 6891 3191 500701 58447 550402 36282 0.494 
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Table 2.6. LC-MS/MS analysis of TCS metabolism by gut bacteria. 
 
 Reaction product analyzed by LC-MS/MS 
(expressed as peak area from MS) 
Assay Hydroxyl-TCS Hydroxyl-TCS 
glucuronide 
Hydroxyl- TCS 
sulfate 
DMSO, w/o bacteria <Limit of 
detection (LOD) 
<LOD <LOD 
DMSO, w/ mouse fecal bacteria <LOD <LOD <LOD 
DMSO, w/ human stool bacteria <LOD <LOD <LOD 
DMSO, w/ bacteria from mouse 
small intestine 
<LOD <LOD <LOD 
DMSO, w/ bacteria from mouse 
cecum 
<LOD <LOD <LOD 
DMSO, w/ bacteria from mouse 
colon 
<LOD <LOD <LOD 
 
TCS (20 µM dissolved 
in DMSO), w/o bacteria 
<LOD <LOD <LOD 
 
TCS, w/ mouse fecal bacteria <LOD <LOD <LOD 
TCS, w/ human stool bacteria <LOD <LOD <LOD 
TCS, w/ bacteria from mouse 
small intestine 
<LOD <LOD <LOD 
TCS, w/ bacteria from mouse 
cecum 
<LOD <LOD <LOD 
TCS, w/ bacteria from mouse 
colon 
<LOD <LOD <LOD 
Note: in all assays as shown above, we did not detect the formation of hydroxyl-TCS 
species (while we successfully detected hydroxyl-TCS species in animal tissues, see 
Figure 2.2), suggesting that at least the culturable bacteria can’t convert TCS to hydroxyl-
TCS in vitro. 
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Table 2.7. Concentrations of free-form TCS, TCS glucuronide, and TCS sulfate in 
human urine after treatment. 
See the scheme of the human experiment in Figure 2.9A. 
 
 TCS metabolites (pmol/μL urine) 
 
Human 
subject # 
 
 
Treatment 
 
Treatment 
time (months) 
 
 
TCS 
 
 
TCS glucuronide 
 
 
TCS sulfate 
5 no TCS 0 < LOD * < LOD < LOD 
9 no TCS 0 < LOD 5.52 0.0016 
16 no TCS 0 < LOD 0.04 < LOD 
14 no TCS 1 < LOD 0.41 < LOD 
7 no TCS 3 < LOD 0.02 < LOD 
5 no TCS 4 < LOD < LOD < LOD 
6 no TCS 4 < LOD < LOD < LOD 
7 no TCS 4 < LOD < LOD < LOD 
9 no TCS 4 < LOD < LOD < LOD 
16 no TCS 4 0.0642 0.71 < LOD 
3 TCS 0 < LOD 0.18 0.0007 
4 TCS 0 < LOD 0.03 < LOD 
8 TCS 0 < LOD < LOD < LOD 
12 TCS 0 < LOD 0.13 < LOD 
12 TCS 1 < LOD 6.26 0.0047 
12 TCS 2 0.0855 9.53 0.0052 
13 TCS 3 < LOD 7.71 0.0016 
3 TCS 4 0.1123 13.73 0.0069 
4 TCS 4 0.0552 7.75 0.0039 
13 TCS 4 0.0306 10.37 0.0026 
* LOD: limit of detection 
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Table 2.8. LC-MS/MS semi-quantification of hydroxyl-TCS, hydroxyl-TCS 
glucuronide, and hydroxyl-TCS sulfate in human urine after treatment. 
See the scheme of the human experiment in Figure 2.9A 
 
 TCS metabolites (Peak area/ μL urine) 
 
Human 
subject # 
 
 
Treatment 
 
Treatment 
time (months) 
 
 
Hydroxyl-
TCS 
 
Hydroxyl-TCS 
glucuronide 
 
Hydroxyl-TCS 
sulfate 
5 
9 
16 
14 
7 
5 
6 
7 
9 
no TCS 
no TCS 
no TCS 
no TCS 
no TCS 
no TCS 
no TCS 
no TCS 
no TCS 
0 
0 
0 
1 
3 
4 
4 
4 
4 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
22627 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
68139 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
< LOD 
16 no TCS 4 < LOD < LOD < LOD 
3 TCS 0 < LOD < LOD < LOD 
4 TCS 0 < LOD < LOD < LOD 
8 TCS 0 < LOD < LOD < LOD 
12 TCS 0 < LOD < LOD < LOD 
12 TCS 1 < LOD 5683 49464 
12 TCS 2 < LOD 31321 148435 
13 TCS 3 < LOD 61177 161848 
3 TCS 4 < LOD 106569 66047 
4 TCS 4 < LOD 8887 28240 
13 TCS 4 < LOD 53570 165006 
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Table 2.9. Concentrations of free-form TCS, TCS glucuronide, and TCS sulfate in human stool after treatment. 
See the scheme of the human experiment in Figure 2.9A. 
 TCS metabolites (pmol/ g stool) 
 
Human 
subject # 
 
 
Treatment 
Treatment 
time (months) 
 
 
TCS 
 
 
TCS glucuronide 
 
 
TCS sulfate 
2 no TCS 0 14.93 < LOD < LOD 
5 no TCS 0 13.15 5.21 < LOD 
6 no TCS 0 10.10 < LOD < LOD 
7 no TCS 0 23.67 < LOD < LOD 
9 no TCS 0 540.07 < LOD < LOD 
11 no TCS 0 19.95 < LOD < LOD 
14 no TCS 0 10.11 < LOD < LOD 
16 no TCS 0 57.90 < LOD < LOD 
2 no TCS 1 22.49 < LOD < LOD 
5 no TCS 1 13.96 < LOD < LOD 
6 no TCS 1 18.83 < LOD < LOD 
7 no TCS 1 9.65 4.99 < LOD 
9 no TCS 1 25.43 21.75 < LOD 
11 no TCS 1 < LOD < LOD < LOD 
14 no TCS 1 14.00 < LOD < LOD 
16 no TCS 1 317.47 < LOD < LOD 
5 no TCS 2 22.69 < LOD < LOD 
6 no TCS 2 29.34 < LOD < LOD 
7 no TCS 2 19.95 < LOD < LOD 
9 no TCS 2 14.40 < LOD < LOD 
11 no TCS 2 < LOD < LOD < LOD 
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14 no TCS 2 56.73 < LOD < LOD 
16 no TCS 2 96.24 < LOD < LOD 
2 no TCS 3 11.79 17.62 < LOD 
5 no TCS 3 7.44 < LOD < LOD 
6 no TCS 3 < LOD < LOD < LOD 
7 no TCS 3 5.90 < LOD < LOD 
9 no TCS 3 7.60 < LOD < LOD 
11 no TCS 3 7.75 < LOD < LOD 
14 no TCS 3 11.01 16.46 < LOD 
16 no TCS 3 105.82 < LOD < LOD 
2 no TCS 4 < LOD < LOD < LOD 
5 no TCS 4 20.54 < LOD < LOD 
6 no TCS 4 < LOD < LOD < LOD 
7 no TCS 4 8.75 < LOD < LOD 
9 no TCS 4 7.48 14.59 < LOD 
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Table 2.10. LC-MS/MS semi-quantification of hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS sulfate in human 
stool after treatment. 
See the scheme of the human experiment in Figure 2.9A. 
 
 TCS metabolites (pmol/ g stool) 
 
 
Subject # 
 
 
Treatment 
 
Treatment time 
(months) 
 
 
Hydroxyl-TCS 
 
Hydroxyl-TCS 
glucuronide 
 
Hydroxyl-TCS 
sulfate 
2 no TCS 0 < LOD < LOD < LOD 
5 no TCS 0 < LOD < LOD < LOD 
6 no TCS 0 < LOD < LOD < LOD 
7 no TCS 0 < LOD < LOD < LOD 
9 no TCS 0 10754 < LOD < LOD 
11 no TCS 0 < LOD < LOD < LOD 
14 no TCS 0 < LOD < LOD < LOD 
16 no TCS 0 < LOD < LOD < LOD 
2 no TCS 1 < LOD < LOD < LOD 
5 no TCS 1 < LOD < LOD < LOD 
6 no TCS 1 < LOD < LOD < LOD 
7 no TCS 1 < LOD < LOD < LOD 
9 no TCS 1 < LOD < LOD < LOD 
11 no TCS 1 < LOD < LOD < LOD 
14 no TCS 1 < LOD < LOD < LOD 
16 no TCS 1 < LOD < LOD < LOD 
5 no TCS 2 < LOD < LOD < LOD 
6 no TCS 2 < LOD < LOD < LOD 
7 no TCS 2 < LOD < LOD < LOD 
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9 no TCS 2 < LOD < LOD < LOD 
11 no TCS 2 < LOD < LOD < LOD 
14 no TCS 2 < LOD < LOD < LOD 
16 no TCS 2 < LOD < LOD < LOD 
2 no TCS 3 2410 < LOD < LOD 
5 no TCS 3 < LOD < LOD < LOD 
6 no TCS 3 < LOD < LOD < LOD 
7 no TCS 3 < LOD < LOD < LOD 
9 no TCS 3 554 < LOD < LOD 
11 no TCS 3 < LOD < LOD < LOD 
14 no TCS 3 < LOD < LOD < LOD 
16 no TCS 3 < LOD < LOD < LOD 
2 no TCS 4 < LOD < LOD < LOD 
5 no TCS 4 < LOD < LOD < LOD 
6 no TCS 4 < LOD < LOD < LOD 
7 no TCS 4 < LOD < LOD < LOD 
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Figure 2.1. Upon TCS exposure, the dominant metabolites in most organs are TCS 
conjugates (TCS glucuronide and TCS sulfate), while the dominant compound in 
the digesta of cecum and colon is free- from TCS.  
(A) Chemical structures of TCS, TCS glucuronide, and TCS sulfate. (B) LC-MS/MS 
quantification of the tissue concentrations of free-form TCS and TCS conjugates. SI: 
small intestine. The data are mean ± SEM, n = 10 mice per group. 
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Figure 2.2. Antibiotic cocktail-mediated suppression of gut microbiota reduces 
concentrations of free-from TCS species, while enhancing concentrations of TCS 
conjugates in colon digesta.  
(A) Scheme of animal experiment. (B-E) LC-MS/MS quantification of (B) free-form 
TCS, TCS conjugates (a combination of TCS glucuronide and TCS sulfate), (C) 
hydroxyl-TCS, (D) hydroxyl-TCS glucuronide, and (E) hydroxyl-TCS sulfate in colon 
digesta. The data are mean ± SEM, n = 5 mice per group for Veh or ABX group, and n = 
10 mice per group for TCS or TCS + ABX group. Statistical significance of the 
interaction effect between ABX (ABX versus water) and treatment (TCS versus vehicle) 
on TCS species was determined by two-way ANOVA. 
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Figure 2.3 Treatment with antibiotic cocktail (ABX) ablated bacteria in colons of 
mice.  
(A) Scheme of animal experiment (modified from Figure 2.2A): at day 0 (5 days after 
ABX treatment) and day 28 (end of the experiment), the total fecal microbial biomass 
was analyzed by qPCR of 16S rRNA gene. (B) 16S rRNA gene copies in mouse feces on 
day 0 (n = 20 per group). (C) 16S rRNA gene copies in mouse feces on day 28 (n = 10 
per group). The data are mean ± SEM, ***P < 0.001, **** P<0.0001. 
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Figure 2.4. Identification of hydroxylated metabolites in colon digesta by UHPLC-
Orbitrap Fusion MS. 
(A) Chromatogram of hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS 
sulfate. (B-D) Product ion spectra and proposed structures of m/z 302.9388 
(hydroxyl-TCS, B), m/z 478.9709 (hydroxyl-TCS glucuronide, C), and m/z 382.8956 
(hydroxyl-TCS sulfate, D). 
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Figure 2.5. Gut bacteria mediates TCS metabolism in vitro. 
(A) Scheme of experiment: TCS glucuronide was incubated with gut bacteria, and the 
formation of free-form TCS was quantified by LC-MS/MS. (B) Effects of fecal 
microbiota from mice or humans on converting TCS glucuronide to TCS. (C) Effects of 
pure bacterial strains on converting TCS glucuronide to TCS. The data are mean ± SEM, 
n = 3 per group, *P < 0.05, ***P < 0.001, ****P < 0.0001. Statistical significance was 
determined using one-way ANOVA. 
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Figure 2.6. TCS glucuronide treatment has no effect on bacterial growth.   
Growth curves of L. brevis, L. rhamnosus, L. reuteri DSM 20053, L. reuteri DSM 20016, 
and B. longum after 30 h treatment with vehicle or 20 µM TCS glucuronide. The data are 
mean ± SEM, n = 3 from three independent experiments. 
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Figure 2.7. TCS treatment has no effect on bacteria growth. 
Growth curves of L. rhamnosus, L. gasseri, B. breve, B. bifidum and B. 
pseudocatenulatum after 30 h treatment with vehicle, 0.1 µM, or 0.1 µM TCS. The data 
are mean ± SEM, n = 3 from three independent experiments. 
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Figure 2.8. Relative abundance of certain bacterial strains after exposure to TCS in 
mice.  
(A) Scheme of animal experiment (adapted from Figure 2.2A): the mice were treated with 
TCS (80 ppm in diet) or vehicle via diet for 4 weeks, then the relative abundance of 
certain bacterial strains in the mouse feces were analyzed by qPCR using strain-specific 
primers. (B) The relative abundance of B. breve and L. brevis. The data are mean ± SEM, 
n = 10 per group, statistical significance was determined using Student’s t-test. 
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Figure 2.9. Upon TCS exposure, the dominant metabolites in human urine are TCS 
conjugates, while the dominant compound in human stool is free-form TCS.  
(A) Scheme of experiment: human subjects were exposed to personal care products 
without TCS (control group), or exposed to personal care products containing TCS (TCS 
group) for 4 months. At 0, 1, 2, 3, and 4 months, the urine and stool samples were 
collected for analysis. (B) LC-MS/MS profiling of TCS metabolism in human urine. (C) 
LC-MS/MS profiling of TCS metabolism in human stool. The data are mean ± SEM. 
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Figure 2.10. TCS, but not TCS glucuronide or TCS sulfate, increases inflammatory 
responses in MC38 colon cancer cells. 
(A) Gene expression of inflammatory cytokines and (B) ELISA analysis of cytokines in 
cell culture medium after treatment with vehicle, TCS, TCS glucuronide, or TCS sulfate 
for 48 h. The data are mean ± SEM, n = 3 per group from three independent experiments, 
* P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was 
determined using one-way ANOVA. 
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Figure 2.11. Effects of free-form TCS on human gut microbiota in vitro. 
(A) Scheme of experiment. (B) Effects of TCS on diversity of human stool microbiota. 
(C) Individual relative abundance at phylum level (n = 8 per group). C: control group 
(treated with vehicle DMSO), T: treatment group (treated with 10 nM TCS). Volunteers 
1-4 are male, and volunteers 5-8 are female. (D) Effect of TCS on relative abundance of 
specific bacteria phylum (n = 8 per group). The Y-axis is expressed as relative abundance 
of treatment group to control group for each individual volunteer. The results are mean ± 
SEM, ** P < 0.01, *** P < 0.001. 
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Figure 2.12. Exposure to TCS modulated composition of gut microbiota at genus 
levels in human fecal bacteria in vitro.  
(A) Individual relative abundance at genus level (n = 8 per group). C: control group 
(treated with vehicle DMSO), T: treatment group (treated with 10 nM TCS). Volunteer 1-
4 are male, and volunteer 5-8 are female.  (B) Effect of TCS on relative abundance of 
specific bacteria genera (n = 8 per group). The Y-axis is expressed as relative abundance 
of treatment group to control group for each individual volunteer. The results are mean ± 
SEM, ** P < 0.01, *** P < 0.001. 
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Figure 2.13. Proposed model: gut bacteria mediates colonic metabolism of TCS, 
leading to metabolic re- activation of TCS and resulting in enhanced colonic 
inflammation. 
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CHAPTER 3 
 
TRICLOCARBAN EXPOSURE EXAGGERATES COLONIC INFLAMMATION 
AND COLON TUMORIGENESIS BY ALTERING GUT MICROBIOTA 
3.1 Introduction 
Triclocarban (3,4,4'-trichlorocarbanilide, TCC) has been used as an antimicrobial 
ingredient for more than 60 years, and is incorporated into many consumer products such 
as bar soaps, deodorants and detergents 8. Each year, U.S. consumers are exposed to 
approximate 500,000 pounds of TCC from personal care products 8. The 2013–2014 
National Health and Nutrition Examination Survey showed that 36.9% of urine samples 
in the United States contained TCC 146. The majority of used TCC is ultimately released 
into the environment leading to widespread pollution. As a result, TCC was listed as a 
top-10 contaminant in U.S. rivers 8. More alarmingly, recent studies showed that 
environmental TCC could be efficiently taken up by food crops, leading to the 
bioaccumulation of TCC and potential human exposure through food consumption. 
Notably, Mathews et al. showed that some common food crops, such as broccoli, potato, 
beat, cabbage, and pepper, can accumulate >100 ppm TCC in the root tissues, and onions 
can accumulate >800 ppm TCC in the bulbs 147. The results from this study are supported 
by many other investigations 148-155. Together, the ubiquitous presence of TCC has raised 
concern about its impact on the environment and human health.  
The regulatory policy of TCC is an intensively debated topic now. In 2016, the 
FDA removed TCC from over-the-counter handwashing products 156. This decision was 
mainly based on recent studies which showed that compared with plain soaps, the 
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antimicrobial soaps containing TCC did not provide additional health benefits 157; 
therefore, high-volume low-value use of TCC in handwashing products was not further 
allowed by the FDA 156. This ruling only affects over-the-counter handwashing products, 
but TCC remains approved by the FDA and the EPA for use in many other consumer 
products. A better understanding of the impact of TCC on human health could be 
important to prepare possible further regulatory policies of this compound.  
Previous studies for TCC toxicology have focused on endocrine function 158-164, 
however the effects of TCC on other human disorders are largely unknown. Our recent 
studies showed that exposure to other consumer antimicrobials, such as triclosan, 
benzalkonium chloride, and benzethonium chloride, exaggerates the severity of colitis 
and exacerbates the development of colon tumorigenesis in mouse models, through gut 
microbiota-dependent mechanisms 121,165. To date, the effects of TCC on gut health are 
unknown. Here we studied the actions and mechanisms of TCC on colitis and colitis-
associated colon tumorigenesis in animal models.   
3.2 Materials and Methods 
3.2.1 Animal experiments 
All animal experiments were conducted in accordance with the protocol approved 
by the Institutional Animal Care and Use Committee (IACUC) of the University of 
Massachusetts Amherst. The mice were maintained in a standard specific-pathogen free 
(SPF) animal facility. To facilitate the microbiota study, after mouse arrival, the mice 
were rotated between different cages during the adaptation period, then the mice were 
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randomized to different treatment groups (2-3 mice per cage). These procedures are 
expected to mitigate potential cage effects on gut microbiota 166,167. 
3.2.2 Dextran sodium sulfate (DSS)-induced colitis model 
C57BL/6 male mice (six-week-old, Charles River, Wilmington, MA) were 
randomly divided into control and treatment groups (n = 8 for each group). The mice in 
the control group were treated with a modified AIN-93G diet (Table 3.1) containing 0.5% 
v/w polyethylene glycol 400 (PEG 400, EMD Millipore, Billerica, MA), and the mice in 
the treatment group were treated with the diet containing TCC (99%, Sigma-Aldrich, St. 
Louis, MO) dissolved in PEG 400 during the whole experiment. After 3 weeks, the mice 
were treated with 2% DSS (36–50 kDa, MP Biomedicals, Solon, OH) in drinking water 
to induce acute colitis. After 9 days, the mice were sacrificed, and the blood and colon 
tissues were collected for analysis.  
3.2.3 Interleukin-10 (Il-10)-/- colitis model 
Il-10-/- male mice (five-week-old, stock No. 002251, JAX, Bar Harbor, ME) were 
randomly divided into control and treatment groups (n = 8 for each group). The mice 
were fed with the modified AIN-93G diet containing PEG 400 (0.5% v/w) or 80 ppm 
TCC dissolved in PEG 400 during the whole experiment. Standard sterilized water was 
supplied in bottles ad libitum. After 12 weeks, the mice were treated with 200 ppm 
piroxicam (Sigma-Aldrich, St. Louis, MO) via diet to accelerate development of colitis 
168. After 1 week, the mice were sacrificed, and the blood and colon tissues were 
collected for analysis. 
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3.2.4 Azoxymethane (AOM)/DSS-induced colorectal tumorigenesis model 
C57BL/6 male mice (six-week-old) were acclimated for 1 week and randomized 
into control and treatment groups (n = 16 for each group). The mice were fed with the 
modified AIN-93G diet containing PEG 400 (0.5% v/w) or 80 ppm TCC dissolved in 
PEG 400 during the whole experiment. After 3 weeks, the mice were treated with 10 
mg/kg AOM (Sigma-Aldrich, St. Louis, MO) via intraperitoneal injection. After 1 week, 
they were given 2% DSS in drinking water for 1 week. At day 50 post the AOM 
injection, the mice were sacrificed, and the blood and colon tissues of the mice were 
collected for analysis.  
3.2.5 Antibiotic cocktail-mediated suppression of gut microbiota  
C57BL/6 male mice (five-week-old) were treated with drinking water with or 
without a broad-spectrum antibiotic cocktail (1.0 g/L ampicillin and 0.5 g/L neomycin) 
during the whole experiment 133,134. After 4 days, the mice were treated with the modified 
AIN-93G diet containing 80 ppm TCC or vehicle (PEG 400) until the end of the 
experiment. After 3 weeks of diet treatment, the mice were stimulated with 2% DSS for 8 
days in drinking water to induce colitis. At the end of the experiment, the mice were 
sacrificed, and the blood and colon tissues were collected for analysis.  
3.2.6 Flow cytometry analysis 
The distal colon tissues from the mice were dissected, washed with cold PBS, and 
digested with Hank's-balanced salt solution (HBSS, Lonza, Basel, Switzerland) 
supplemented with 1 mM dithiothreitol (DTT) and 5 mM ethylenediaminetetraacetic acid 
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(EDTA) for 2 h at 4 °C. The single cell suspensions were filtered through 70 μm cell 
filters (BD Biosciences, San Jose, CA). The cells were stained with APC-conjugated anti-
mouse CD11c antibody, FITC-conjugated anti-mouse CD45 antibody, PE/Cy7-
conjugated anti-mouse Ly-6G/Ly-6C (Gr-1) antibody, PerCP/Cy5.5-conjugated anti-
mouse F4/80 antibody, and isotype control antibody according to the manufacturer’s 
instructions (BioLegend, San Diego, CA). The stained cells were analyzed using BD 
LSRFortessa™ cell analyzer (BD Biosciences, San Jose, CA) and data were analyzed 
using FlowJo software (FlowJo LLC, Ashland, OR). In our analysis, leukocytes were 
identified as CD45+ cells and macrophages were identified as CD45+ F4/80+ cells. 
3.2.7 ELISA analysis of cytokines in plasma 
The blood samples were harvested via cardiac puncture, and the plasma fractions 
were prepared by centrifugation of the blood at 1,500 g for 10 min at 4 ˚C. The 
concentrations of cytokines in plasma were determined using a CBA Mouse 
Inflammation Kit (BD Biosciences) according to the manufacturer’s instruction.  
3.2.8 RT-qPCR analysis 
The colon tissues were frozen by liquid nitrogen and ground. Total RNA was 
isolated from the colon tissues using TRIzol reagent (Ambion, Austin, TX) according to 
the manufacturer’s instructions. The RNA was reverse transcribed into cDNA using a 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s instruction. RT-qPCR was carried out with a DNA 
Engine Opticon system (Bio-Rad Laboratories, Hercules, CA) with Maxima SYBR-green 
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Master Mix (Thermo Fisher Scientific). The sequences of mouse-specific primers 
(Thermo Fisher Scientific) were listed in Table 3.2. Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) was used as an internal control.  
3.2.9 Hematoxylin and eosin (H&E) staining 
The dissected colon tissues were fixed in 4% formalin (Thermo Fisher Scientific) 
for 24 h, embedded into paraffin (Thermo Fisher Scientific), and sliced into 5-μm 
sections. For H&E staining, the slides were stained with hematoxylin and eosin (Sigma-
Aldrich), and examined with a light microscope. The histological scores were evaluated 
by blind observers according to the crypt architecture, degree of inflammatory cell 
infiltration, muscle thickening, and goblet cell depletion of the tissue. The histological 
damage score is the sum of each individual score.  
3.2.10 Immunohistochemistry (IHC) 
The sections were prepared and heated in 0.01 M citrate buffer (pH 6.0) for 20 
minutes in a PT Module antigen retrieval device (Thermo Fisher Scientific). The 
antibodies against mouse PCNA and β-catenin (Cell Signaling Technology) were 
incubated overnight at 4 °C. Horseradish peroxidase (HRP)-conjugated secondary 
antibodies were then applied to the sections, followed by chromogen 4-diaminobenzidine 
(Dako, Carpinteria, CA) staining. Sections were then counterstained with hematoxylin for 
2 minutes. Positive expression was observed under a light microscope.  
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3.2.11 16S rRNA sequencing of fecal microbiota 
C57BL/6 male mice (six-week-old) were maintained on a modified AIN-93G diet 
containing PEG 400 (0.5% v/w) or 80 ppm TCC dissolved in PEG 400 for 3 weeks. The 
feces were collected for microbiota analysis. The total fecal DNA was extracted using 
QIAamp DNA Stool Mini Kit (Qiagen) following the manufacturer’s instruction with the 
addition of the bead-beating step. The quality of the extracted DNA was measured using 
a NanoDrop Spectrophotometer (Thermo Scientific) and verified using gel 
electrophoresis. PCRs were performed in a 96-well format on a Veriti thermal cycler 
(Life Technology) with 2 × KAPA HiFi Hotstart ReadyMix (KAPA Biosystem) using 
primers specific for the V3-V4 region of the 16s rRNA gene (see Table 3.2). After 
purification with AMPure XP beads (Beckman Coulter), a limited cycle PCR was 
performed using the Nextera XT Index Kit (Illumina) to attach dual indices and Illumina 
sequencing adapters, followed by an additional purification with AMPure XP bead. The 
quantity of the purified PCR products was measured using a Qubit dsDNA BR Assay kit 
(Life technology) and the amplicon quality was estimated by ScreenTape Assay on Tape 
Station 2200 (Agilent). After quantification and qualification, samples were pooled in 
equimolar amount and pair-end 2*300bp sequencing was performed on an Illumina 
MiSeq platform using a Miseq reagent kit V3 (8% PhiX) (Illumina). The sequencing data 
was processed by QIIME software pipeline v1.9.1. In general, the high-quality sequence 
data (quality value ≥ 30) was demultiplexed. Sequences were then clustered into 
operational taxonomic unites (OTUs) using Open reference OTU picking against 
Greengenes bacterial 16S rRNA database (13_8 release) with a 97% similarity threshold. 
The α-diversity (the diversity within sample community species richness) was determined 
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with ten iterations at a maximal sequence depth where all samples could be included. The 
β-diversity (dissimilarity among different treatment groups) was calculated using 
weighted and un-weighted UniFrac distances.  
3.2.12 Culture of Bifidobacterium infantis 272 
B. infantis 272 (ATCC, Manassas, VA) was subcultured at 37 °C in MRS broth 
(Thermo Fisher Scientific) containing 0.5 g/L L-cysteine in an anaerobic cabinet 
(Whitley A35 anaerobic workstation, Don Whitley Scientific, Shipley, England) under an 
atmosphere of 85% N2, 10% CO2, and 5% H2. The B. infantis 272 were inoculated 1:100 
into MRS broth containing TCC or DMSO vehicle and then incubated at 37 °C in 
anaerobic conditions for 48 h. Bacterial growth was monitored by measuring the turbidity 
at 600 nm.  
3.2.13 Data analysis 
Data are expressed as the mean ± standard error of the mean (SEM). Statistical 
comparison of two groups was performed using Student’s t-test or Wilcoxon-Mann-
Whitney test, and comparison of three or more groups was analyzed by one-way 
ANOVA followed by Tukey’s post hoc test. Analysis of inflammation in antibiotics-
treated mouse experiments was performed by two-way ANOVA, followed by Tukey-
Kramer’s method, and H&E histology data was analyzed by two-way ANOVA Poisson 
Generalized Linear Model, followed by the Tukey-Kramer’s multiple comparison 
method. P < 0.05 were considered statistically significant. 
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3.3 Results 
3.3.1 TCC increased DSS-induced colitis in mice 
To determine the effect of TCC on colonic inflammation, we studied its effect on 
colitis using a well-established DSS-induced colitis model in C57BL/6 mice 169. 
Treatment with TCC via diet (80 ppm in diet, administering TCC at a dose of ~8 
mg/kg/day, based on a diet of 3 g daily chow) exaggerated DSS-induced colitis in mice 
(Figure 3.1). Compared with vehicle control, treatment with TCC exacerbated body 
weight loss (Figure 3.1A), exacerbated colon length reduction (Figure 3.1B), increased 
plasma concentrations of the pro-inflammatory cytokine IL-6 (Figure 3.1C), up-regulated 
the gene expression of Il-6 in the colon (Figure 3.1D), increased infiltration of leukocytes 
(CD45+) into the colon (Figure 3.1E), and exaggerated crypt damage in the colon (Figure 
3.1F). We also tested the effect of a low-dose TCC (10 ppm in diet) and found that TCC 
also exaggerated DSS-induced colitis (Figure 3.2). Together, these results demonstrate 
the pro-colitis effect of TCC in vivo.  
3.3.2 TCC increased colitis in Il-10-/- mice  
To further validate the pro-colitis effect of TCC, we tested its action on 
spontaneous colitis using a genetically engineered Il-10-/- mouse model 168. Treatment 
with TCC via diet (80 ppm in diet, administering TCC at a dose of ~8 mg/kg/day, based 
on a diet of 3 g daily chow) exaggerated colitis in Il-10-/- mice (Figure 3.3). Compared 
with the vehicle control, treatment with TCC reduced the colon length (Figure 3.3A, P < 
0.05), increased the gene expression of Il-6 in the colon (Figure 3.3B, P < 0.05), 
enhanced infiltration of leukocytes (CD45+) into the colon (Figure 3.3C, P < 0.01), and 
 73 
 
exaggerated crypt damage in the colon (Figure 3.3D, P < 0.05). These results further 
validate that exposure to TCC exaggerated colitis in vivo. 
3.3.3 TCC increased AOM/DSS-induced colon tumorigenesis in mice 
We tested the effect of TCC on colitis-associated colon tumorigenesis using a 
well-established AOM/DSS-induced colon cancer model in C57BL/6 mice 170. Treatment 
with TCC via diet (80 ppm in diet) increased AOM/DSS-induced colon tumorigenesis in 
mice (Figure 3.4). Compared with the vehicle control, treatment with TCC reduced 
overall survival of the mice (Figure 3.4A). Regarding colon tumorigenesis, TCC 
increased the tumor number, tumor size, and total tumor burden in mice (Figure 3.4B, P 
< 0.01), illustrating its pro-tumorigenic effect. Consistent with enhanced colon 
tumorigenesis, immunohistochemical staining showed that TCC increased protein levels 
of proliferating cell nuclear antigen (PCNA, a marker of tumor proliferation, P < 0.01) 
and β-catenin (a marker of the pro-tumorigenic Wnt pathway, P < 0.001) in colon tumors 
(Figure 3.4C). In addition, qRT-PCR showed that TCC treatment increased expressions 
of c-Myc and Axin2 (markers of Wnt pathway) in colon tumors (Figure 3.4D, P < 0.05), 
further supporting that TCC enhanced activation of the pro-tumorigenic Wnt pathway in 
vivo. Inflammation plays a central role in colon tumorigenesis 171. Compared with the 
vehicle control, TCC increased gene expressions of Il-6 and Tnf-α in colon tumors 
(Figure 3.4D, P < 0.05), and enhanced infiltration of leukocytes (CD45+) and 
macrophages (CD45+ F4/80+) into colon tumors (Figure 3.4E, P < 0.01), illustrating its 
enhancing effect on tumor inflammation. Together, these results demonstrate that 
exposure to TCC exaggerated colitis-associated colon tumorigenesis in vivo.  
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3.3.4 TCC reduced the diversity and changed the composition of gut microbiota in 
mice 
 
Gut microbiota plays a central role in regulating colonic inflammation and colon 
tumorigenesis 172. We studied the effect of TCC on gut microbiota in C57BL/6 mice. 
Treatment with TCC via diet (80 ppm in diet) for 3 weeks decreased the a-diversity of 
the gut microbiota, as assessed by PD-whole tree analysis (Figure 3.5A, P < 0.001), and 
modulated the b-diversity of the microbiota, as assessed by principle coordinate analysis 
(Figure 3.5B, P < 0.01). Regarding the composition of the gut microbiota, exposure to 
TCC altered the relative bacterial abundance at both phylum and genus levels (Figure 
3.5C-D, Table 3.3-3.4). Notably, TCC increased the abundance of Proteobacteria (Figure 
3.5C, Table 3.3, P < 0.05), which has been shown to be increased in inflammatory bowel 
disease (IBD) patients and is associated with the pathogenesis of IBD 137. TCC also 
reduced the abundance of Bifidobacterium (Figure 3.5D, Table 3.4, P < 0.05), which has 
been shown to have anti-inflammatory effects 173. Together, these results showed that 
exposure to TCC could cause adverse effects on gut microbiota. 
3.3.5 TCC inhibited growth of Bifidobacterium bacteria in vitro 
Given our findings that TCC reduced the relative abundance of Bifidobacterium 
in gut microbiota in vivo, we studied whether it could directly inhibit the growth of 
Bifidobacterium in vitro. Compared with the vehicle control (DMSO), TCC at a 
concentration of 100 nM inhibited ~30% of the growth of B. infantis 272 (Figure 3.6, P < 
0.05). This result supports that TCC could have direct effects on gut bacteria. 
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3.3.6 TCC increased DSS-induced colitis via gut microbiota-dependent 
mechanisms 
To validate the roles of gut microbiota in the biological actions of TCC, we tested 
whether antibiotic cocktail-mediated suppression of gut microbiota modulates the pro-
colitis effect of TCC (see scheme of animal experiment in Figure 3.7A). We used an 
antibiotic cocktail from previous studies 133,134. We found that a 5-day treatment with this 
cocktail caused a >99% reduction of fecal bacteria, as assessed by qPCR analysis of the 
16S rRNA gene (Figure 3.8), validating that this antibiotic cocktail suppressed gut 
microbiota. Before the DSS stimulation, treatment with TCC and/or the antibiotic 
cocktail had little impact on mouse body weight (Figure 3.9).  
Regarding DSS-induced colitis, two-way ANOVA analysis showed that there was 
a significant interaction (P < 0.05) between TCC treatment (TCC versus vehicle) and 
antibiotic treatment (antibiotic cocktail versus no antibiotic cocktail) on colonic 
inflammation (Figure 3.7B-D). Notably, without antibiotic treatment, TCC exposure 
enhanced crypt damage in the colon while, with antibiotic treatment, the pro-colitis effect 
of TCC was abolished (Figure 3.7D). These results support that gut microbiota play a 
critical role in the pro-colitis effect of TCC in vivo. 
3.4 Discussion 
To date, the effects of TCC on human health are not well understood. Previous 
studies showed that TCC could be a potential endocrine-disrupting compound 158-164; 
besides endocrine function, the effects of TCC on other human disorders are largely 
unknown. Here our central finding is that exposure to TCC exaggerated colonic 
inflammation and colitis-associated colon tumorigenesis in mice. We found that exposure 
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to relatively low-dose TCC via diet (10-80 ppm in diet, administering TCC at a dose of 
~1-8 mg/kg/day, based on a diet of 3 g daily chow) increased disease developments in 
multiple animal models, including DSS-induced acute colitis in C57BL/6 WT mice, 
spontaneous colitis in genetically engineered Il-10-/- mice, and AOM/DSS-induced colon 
tumorigenesis in C57BL/6 WT mice, illustrating its pro-colitis and pro-neoplastic actions. 
A previous study showed that the no-observed-adverse-effect-level (NOAEL) of TCC 
was 75 mg/kg/day 174, which leads to a calculated acceptable daily intake (ADI) of TCC 
to be 0.75 mg/kg/day. This ADI value is comparable to the dose used in our study, as we 
showed that TCC at a dose of ~1 mg/kg/day exacerbated DSS-induced colitis in mice, 
supporting the notion that the observed adverse effects of TCC in animal experiments 
could mimic responses in human exposure to TCC. In addition, previous studies showed 
that many common food crops could accumulate 100-800 ppm TCC 147, therefore, the 
administration method (oral administration) and dose regime (10-80 ppm in diet) used in 
our studies could reflect potential human exposure to TCC. We have to point out that 
there are many challenges to using animal models to study human exposure to TCC: there 
could be significant differences when exposed to TCC via oral intake (e.g. consumption 
of TCC-contaminated water or food) or dermal application (e.g. usage of TCC-containing 
washing products), and there could be significant inter-individual variations in exposure 
level, absorption, and metabolism of TCC. Together, our results suggest that TCC could 
be a novel environmental risk factor for IBD and colitis-associated colon cancer. Due to 
the ubiquitous presence of TCC in our environment and possibly in our food system, it is 
of critical importance to better understand the actions of TCC on IBD and colitis-
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associated colon cancer, in order to prepare for further regulation policies of this 
compound.   
Our studies support that gut microbiota contributes to the pro-colitis effects of 
TCC. First, we found that exposure to TCC reduced the diversity of the gut microbiota in 
mice. This finding is in agreement with a previous study which showed that exposure to 
TCC caused dysbiosis in rats 175. Previous studies have constantly shown that compared 
with healthy individuals, IBD patients have reduced diversity of gut microbiota, 
suggesting that a reduction of microbial diversity could be correlated with adverse 
outcomes of gut health 176. Second, we found that exposure to TCC increased abundance 
of potentially harmful bacteria, and reduced abundance of beneficial bacteria in mouse 
gut microbiota. Notably, TCC increased the abundance of Proteobacteria phylum, which 
has been shown to be expanded in the gut microbiota of IBD patients, and associated with 
the pathogenesis of IBD 137. In addition, TCC treatment caused a ~75% reduction of the 
abundance of Bifidobacterium, which has been shown to have anti-inflammatory effects 
173. We further found that treatment with TCC at a concentration of 100 nM inhibited the 
growth of B. infantis in vitro, suggesting that TCC could have a direct effect on 
Bifidobacterium. Though there is no study of colonic concentrations of TCC in humans, 
previous studies showed that after a routine usage of TCC-containing personal care 
products, the blood concentrations of TCC in humans can reach up to ~500 nM 177, 
supporting that the dose used in our in vitro experiment (100 nM) is biologically relevant. 
The TCC-induced changes of Bifidobacterium and Proteobacteria are consistent with the 
pro-colitis effect of TCC, but more studies are needed to validate the contributions of 
these gut bacteria in the biological actions of TCC. Finally, we showed that TCC failed to 
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promote DSS-induced colitis in antibiotic cocktail-treated mice, supporting that gut 
microbiota is required for the pro-colitis effect of TCC. We have to mention that there are 
limitations to using the antibiotic cocktail strategy to study the roles of gut microbiota 
involved 178. More studies are needed to elucidate the functional roles of gut microbiota, 
as well as the mucosal immunity, in the biological actions of TCC.  
In summary, here our studies showed that exposure to TCC, a widely used 
antimicrobial ingredient and a ubiquitous contaminant in the environment, exaggerated 
colonic inflammation and colitis-associated colon tumorigenesis in mice, through the 
modulation of gut microbiota. These results showed that TCC could be a novel risk factor 
for IBD and colon cancer. Further studies are needed to better characterize the impact of 
TCC exposure on gastrointestinal diseases in humans in order to prepare for possible 
further regulation of this compound.  
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Table 3.1. Composition of the modified AIN-93G diet used in the animal 
experiment. 
 
Ingredients g/kg 
Casein 200 
L-cystine 3 
Sucrose 100 
Dyetrose 132 
Cornstarch 397.486 
Cellulose 50 
Mineral mix #210025 35 
Vitamin mix #310025 10 
Choline Bitartrate 2.5 
Corn oil (purified) * 70 
Vitamin A Palmitate 0.016 
 
* All ingredients, except corn oil, were purchased from Dyets Inc (Bethlehem, PA). 
Because many commercial corn oil was already oxidized with varied degrees of lipid 
peroxidation, we used purified corn oil for our animal experiment. Briefly, commercial 
corn oil (Mazola®, ACH Food company, Inc., Cordova, TN) was purchased from a local 
market in Amherst, MA, and purified by a silicic acid-activated charcoal chromatography 
to remove any pre-existing oxidized compounds, then the purified oil was fortified with 
400 ppm tocopherols, flushed with N2, and stored at -80°C until use. 
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Table 3.2. Sequences of primers in qRT-PCR and 16S rRNA sequencing. 
 
Gene Forward Reverse 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Tnf-α CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Ifnγ ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC 
Tlr4 ATGGCATGGCTTACACCACC GAGGCCAATTTTGTCTCCACA 
Il-10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 
Il-1β GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
C-myc TGAAGTTCACGTTGAGGGG AGAGCTCCTCGAGCTGTTTG 
Axin 2 TGCATCTCTCTCTGGAGCTG ACTGACCGACGATTCCATGT 
16s rRNA TCGTCGGCAGCGTCAGATGTGTA
TAAGAGACAGCCTACGGGNGGC
WGCAG 
GTCTCGTGGGCTCGGAGATGTGTAT
AAGAGACAGGACTACHVGGGTATC
TAATCC 
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Table 3.3. Effects of TCC on composition of the microbiota at phylum levels. 
(* P < 0.05, ** P < 0.01, *** P < 0.001). Results expressed as relative abundance (%). 
 
 Ctrl  TCC  
Phylum Name Average SEM Average  SEM 
Unassigned 1.290 0.111 0.547 *** 0.092 
Actinobacteria 3.505 0.930 1.091  0.509 
Bacteroidetes 52.984 1.841 32.209 ** 5.054 
Cyanobacteria 0.734 0.163 0.137 *** 0.079 
Deferribacteres 1.686 0.478 0.004 *** 0.002 
Firmicutes 38.873 1.670 62.104 *** 4.437 
Proteobacteria 0.385 0.096 2.048 *** 0.567 
Tenericutes 0.031 0.004 0.054  0.027 
Verrucomicrobia 0.511 0.193 1.806  1.231 
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Table 3.4. Effects of TCC on composition of the microbiota at genus levels. 
The results are expressed as relative abundance (%). (* P < 0.05, ** P < 0.01, *** P < 
0.001) 
 
 
Genus Name 
Ctrl 
 
Average 
 
 
SEM 
TCC 
 
Average 
 
 
SEM 
Unassigned 1.290 0.111 0.547 *** 0.092 
Prauseria 0.004 0.001 0.012 ** 0.004 
Bifidobacterium 3.352 0.922 0.889 * 0.490 
Adlercreutzia 0.145 0.014 0.159 0.034 
Eggerthella 0.000 0.000 0.019 * 0.012 
o Bacteroidales;Other;Other 0.022 0.007 0.002 *** 0.001 
Bacteroides 19.876 2.123 17.980 2.163 
Parabacteroides 13.855 2.009 10.540 2.958 
f Rikenellaceae;g   0.336 0.053 0.224 0.065 
f S24-7;g   13.529 3.403 0.004 *** 0.002 
Butyricimonas 5.362 0.358 3.451 0.935 
o YS2;f ;g   0.734 0.163 0.137 *** 0.079 
Mucispirillum 1.686 0.478 0.004 *** 0.002 
f Bacillaceae;g   0.015 0.002 0.058 * 0.021 
Staphylococcus 0.004 0.002 0.117 0.108 
Enterococcus 0.020 0.007 0.036 0.023 
Lactobacillus 5.887 1.179 2.831 * 1.644 
Streptococcus 0.008 0.001 0.097 0.086 
Turicibacter 0.139 0.053 0.008 * 0.007 
o Clostridiales;Other;Other 0.037 0.008 0.070 * 0.012 
o Clostridiales;f ;g   11.102 1.453 22.917 ** 3.528 
f Christensenellaceae;g   0.110 0.014 0.084 0.020 
f Clostridiaceae;Other 0.014 0.010 0.002 * 0.002 
f Clostridiaceae;g   0.081 0.015 0.390 ** 0.112 
Clostridium 0.009 0.002 0.013 0.003 
Dehalobacterium 0.232 0.027 0.061 *** 0.017 
f Lachnospiraceae;Other 0.339 0.064 0.330 0.025 
f Lachnospiraceae;g   3.937 0.554 7.393 ** 1.097 
Anaerostipes 0.002 0.000 0.011 * 0.003 
Blautia 0.001 0.000 0.003 0.001 
Coprococcus 0.251 0.024 0.771 *** 0.128 
Dorea 0.273 0.117 0.541 * 0.134 
Pseudobutyrivibrio 0.037 0.009 0.007 ** 0.004 
Roseburia 0.013 0.007 0.016 0.006 
[Ruminococcus] 0.528 0.047 1.369 *** 0.211 
f Peptococcaceae;g   0.058 0.012 0.046 0.017 
rc4-4 1.163 0.269 1.762 0.962 
f Peptostreptococcaceae;g_     
_ 0.010 0.006 0.027 0.027 
f Ruminococcaceae;Other 0.806 0.091 0.875 0.169 
f Ruminococcaceae;g   3.514 0.390 7.578 ** 1.361 
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Anaerotruncus 0.013 0.004 0.019 0.007 
Oscillospira 5.521 0.531 6.877 0.851 
Ruminococcus 3.863 0.422 6.806 2.216 
f [Mogibacteriaceae];g   0.031 0.005 0.017 * 0.004 
o SHA-98;f ;g   0.002 0.001 0.000 0.000 
f Erysipelotrichaceae;Other 0.019 0.006 0.011 0.003 
f Erysipelotrichaceae;g   0.795 0.140 0.873 0.179 
Clostridium 0.026 0.006 0.027 0.006 
Coprobacillus 0.007 0.003 0.044 0.025 
o RF32;f ;g   0.125 0.040 0.199 0.092 
Burkholderia 0.019 0.002 0.082 *** 0.044 
f Oxalobacteraceae;Other 0.006 0.001 0.016 ** 0.004 
f Enterobacteriaceae;Other 0.000 0.000 0.004  0.002 
f Enterobacteriaceae;g   0.164 0.038 1.395 *** 0.458 
Enterobacter 0.048 0.031 0.123  0.050 
Klebsiella 0.000 0.000 0.187 ** 0.127 
Stenotrophomonas 0.006 0.001 0.008  0.002 
o RF39;f ;g   0.031 0.004 0.054  0.027 
Akkermansia 0.511 0.193 1.806  1.231 
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Figure 3.1. TCC increased DSS-induced colonic inflammation in C57BL/6 mice. 
(A) Body weight. Left: time-course of body weight; Right: quantification of mouse body 
weight on the final day. (B) Colon length. (C) Concentration of IL-6 in plasma. (D) Gene 
expression of Il-6 in colon. (E) FACS quantification of immune cell infiltration into the 
colon. (F) H&E staining of the colon. The data are mean ± SEM, * P < 0.05, ** P < 0.01, 
n = 8 mice per group. 
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Figure 3.2. Effect of a lower-dose TCC (10 ppm in diet) on DSS-induced colitis in 
mice. 
(A) Body weight. Left: time-course of body weight; Right: quantification of mouse body 
weight on the final day. (B) Colon length. (C) Concentration of IL-6 in plasma. (D) Gene 
expression of Il-6 in colon. (E) FACS quantification of immune cell infiltration into 
colon. (F) H&E staining of the colon. The data are mean ± SEM, * P < 0.05, ** P < 0.01, 
n = 8 mice per group. 
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Figure 3.3. TCC increased the colonic inflammation in Il-10-/- mice.  
(A) Colon length. (B) Gene expression of Il-6 in colon. (C) FACS quantification of 
immune cell infiltration into the colon. (D) H&E staining of the colon. The data are mean 
± SEM, * P < 0.05, ** P < 0.01, n = 8 mice per group. 
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Figure 3.4. TCC increased AOM/DSS-induced colon cancer in C57BL/6 mice.  
(A) Survival curve. (B) Quantification of colon tumors in mice. (C) IHC staining of 
PCNA and β-catenin in colon tumors. (D) Gene expressions in colon tumors. (E) FACS 
quantification of immune cell infiltration into colon tumors. The data are mean ± SEM, * 
P < 0.05, ** P < 0.01, *** P < 0.001, n = 16 mice per group. 
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Figure 3.5. TCC reduced the diversity and altered the composition of gut microbiota 
in C57BL/6 mice.  
(A) α-diversity of the gut microbiota. (B) β-diversity of the gut microbiota, calculated by 
Principle Coordinate Analysis (PCoA) based on weighted UniFrac distance. (C) Relative 
abundance of gut bacteria at phylum levels. (D) Relative abundance of gut bacteria at 
genus levels. The data are mean ± SEM, *** P < 0.01, n = 16 mice per group. 
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Figure 3.6. Effect of TCC on B. infantis 272 growth.  
B. Infantis 272 was treated with TCC or vehicle (DMSO) under anaerobic conditions for 
48 h, then bacterial growth was analyzed by measuring the turbidity at 600 nm. The 
results are expressed as mean ± SEM, from three independent experiments conducted in 
triplicates, * P < 0.05, ** P < 0.01. 
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Figure 3.7. TCC increased DSS-induced colitis via gut microbiota-dependent 
mechanisms.  
(A) Scheme of animal experiment. (B) Colon length. (C) FACS quantification of immune 
cell infiltration into colon. (D) H&E staining of colon. The data are mean ± SEM. The 
statistical significance (P-value) of the interaction effect between TCC treatment (TCC 
versus vehicle control in the diet) and antibiotic treatment (antibiotic cocktail versus no 
antibiotic cocktail in the drinking water) on colitis was determined by two-way ANOVA 
analysis. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 8-10 mice per group. 
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Figure 3.8. Effect of the antibiotic cocktail on fecal bacterial load.  
The mice were given drinking water with or without the antibiotic cocktail (1.0 g/L 
ampicillin and 0.5 g/L neomycin) for 5 days. Feces were collected and 16S rRNA gene 
expression in feces were analyzed by qRT-PCR (n = 7 per group). The results are 
expressed as mean ± SEM, ** P < 0.01. 
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Figure 3.9. Effect of TCC and/or antibiotic cocktail on mouse body weight  
Before the DSS stimulation. The results are expressed as mean ± SEM. 
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CHAPTER 4 
EFFECTS OF CONSUMER ANTIMICROBIALS BENZALKONIUM 
CHLORIDE, BENZETHONIUM CHLORIDE, AMD CHLOROXYLENOL ON 
COLONIC INFLAMMATION AND COLITIS-ASSOCIATED COLON 
TUMORIGENESIS IN MICE 
4.1 Introduction 
Benzalkonium chloride (BAC), benzethonium chloride (BET), and chloroxylenol 
(PCMX) are chemicals used in high-volume as antimicrobial and antibacterial ingredients 
in many consumer, industrial, and medical products, including eye and nasal drops, 
soaps, mouthwash, and cosmetics. Previous studies have shown that these compounds are 
generally well-tolerated in animal models, though there are reports that these compounds 
could cause adverse effects, such as inflammatory responses and genotoxic effects 83-
85,179, mitochondrial dysfunction 180, reproductive dysfunction 81, and developmental 
defects 181. Recent studies show that these compounds, partly due to their high-volume 
use, are frequently detected in river water, sewage effluent, food products, and human 
samples of plasma and serum 37-45. This has raised concern about their impact on the 
environment and human health. In September 2016, the U.S. Food and Drug 
Administration (FDA) removed 19 antimicrobial compounds from consumer antiseptic 
wash products, but deferred rulemaking for BAC, BET, and PCMX to allow additional 
time to develop new safety and efficacy data for these three antimicrobials 156. Therefore, 
it is of critical importance to better understand the effects of these compounds on human 
health, producing knowledge that could have a significant impact on regulatory policies. 
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Inflammatory bowel disease (IBD) is characterized by colonic inflammation, and 
given that it affects ~1.6 million people in the U.S. and ~2.5 million people in Europe 182, 
IBD is a serious health problem in developed countries. IBD patients have elevated risks 
of developing colon cancer: it was estimated that over 20% of IBD patients could develop 
colon cancer within 30 years of diagnosis, and over 50% of these patients could die from 
colon cancer 2. Previous studies performed in cultured cells showed that exposure to these 
compounds caused inflammatory responses and genotoxic effects in vitro 83-85. However, 
to date, the effects of BAC, BET, and PCMX on inflammation and associated 
tumorigenesis in vivo are unknown. Here, we studied the impact of these three 
antimicrobial compounds on colonic inflammation and colitis-associated colon 
tumorigenesis using mouse models. Our results demonstrated that exposure to low doses 
of these antimicrobial compounds, in particular BAC, increased dextran sodium sulfate 
(DSS)-induced colonic inflammation and azoxymethane (AOM)/DSS-induced colon 
tumorigenesis in mice, suggesting that these antimicrobial compounds could have 
potentially adverse effects on gut health.  
4.2 Materials and Methods 
4.2.1 Chemicals  
BAC (purity ≥95%, catalog # AC215411000), BET (purity 97%, catalog # 
AC215411000), and PCMX (purity >98.5%, catalog # AC109061000) were purchased 
from Thermo Fisher Scientific (Waltham, MA). Polyethylene glycol 400 (PEG 400, 
catalog # PX1286B-2) was purchased from EMD Millipore (Billerica, MA). 
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4.2.2 Animal experiments 
C57BL/6 male mice (age = 6 weeks) were purchased from Charles River 
(Wilmington, MA) and were maintained in a standard Specific Pathogen Free (SPF) 
animal facility at the University of Massachusetts Amherst. All animal procedures were 
conducted in accordance with protocols approved by the Institutional Animal Care and 
Use Committee (IACUC) of the University of Massachusetts. At Charles River, bleach- 
and chlorine dioxide-based disinfectants are used in the animal facility; and at UMass, 
hydrogen peroxide-based disinfectants are used to clean surfaces in the animal facility 
(biological safety cabinets, etc.) and BAC-containing products are used to clean the floor 
of the animal facility. Therefore, there is little or no exposure of the mice to 
environmental BAC or other antimicrobials.   
4.2.3 DSS-induced colitis model 
C57BL/6 mice were administered a modified AIN-93G diet (see diet composition 
in Table 4.1) containing 80 ppm BAC, BET, or PCMX (administered at a dose of ~8 
mg/kg body weight/day, based on a diet of 3 g daily chow), or vehicle control (0.5% 
Polyethylene glycol 400) throughout the whole experiment. The diets were mixed 
thoroughly so that the compounds were distributed evenly and changed every 3-4 days. 
After 3 weeks on the diet, the mice were treated with 2% DSS (molecular weight in the 
range of 36–50 kDa, MP Biomedicals, Solon, OH) in drinking water for 7 days to induce 
colonic inflammation. At the end of DSS treatment, the mice were sacrificed for analysis 
of colonic inflammation.   
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4.2.4 Dose-response study of BAC on DSS-induced colitis 
C57BL/6 mice were administered a modified AIN-93G diet containing 5-40 ppm 
BAC (administered at a dose of ~0.5-4 mg/kg body weight/day, based on a diet of 3 g 
daily chow), or vehicle control throughout the whole experiment. After 3 weeks on the 
diet, the mice were treated with 2% DSS in water for 7 days to induce colonic 
inflammation. At the end of DSS treatment, the mice were sacrificed for analysis of 
colonic inflammation.  
4.2.5 AOM/DSS-induced colitis-associated colon cancer model 
The mice were administered a diet containing 40 ppm BAC (administered at a 
dose of ~4 mg/kg body weight/day, based on a diet of 3 g daily chow) or vehicle 
throughout the whole experiment. The diets were mixed thoroughly so that the 
compounds were distributed evenly and changed every 3-4 days.  After 3 weeks on the 
diet, the mice were given intraperitoneal (i.p.) injection of 10 mg/kg AOM (Sigma-
Aldrich, St. Louis, MO). After 1 week, they were treated with 2% DSS in water for 1 
week. On day 50 post the AOM injection, the mice were sacrificed, and blood and colon 
tissues of the mice were collected for analysis.  
4.2.6 Flow cytometry analysis of immune cell infiltration into colon tissues 
Distal colon tissues of the treated mice were dissected, washed with cold PBS, 
and digested with Hank's-balanced salt solution (HBSS, Lonza, Basel, Switzerland) 
supplemented with 1 mM dithiothreitol (DTT) and 5 mM ethylenediaminetetraacetic acid 
(EDTA) for 2 h at 4 °C. The released cells were filtered through 70 μm cell sorters (BD 
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Biosciences, San Jose, CA) to obtain single cell suspensions, which were stained with 
FITC-conjugated anti-mouse CD45 antibody, PE/Cy7-conjugated anti-mouse Ly-6G/Ly-
6C (Gr-1) antibody, PerCP/Cy5.5-conjugated anti-mouse F4/80 antibody, and isotype 
control antibody (BioLegend, San Diego, CA). The stained cells were analyzed using a 
BD LSRFortessa™ cell analyzer (BD Biosciences, San Jose, CA), and data were 
analyzed using the FlowJo software (FlowJo LLC, Ashland, OR). The leukocytes were 
identified as CD45+ cells, neutrophils were identified as CD45+, Gr1+ cells, and 
macrophages were identified as CD45+, F4/80+ cells. Percentages of cells were 
calculated based on total single cells released from distal colon tissues.  
4.2.7 ELISA analysis of cytokines 
Colon tissues were cut open longitudinally, washed with PBS buffer containing 
penicillin (100 U/mL) and streptomycin (100 μg/mL) (Lonza, Basel, Switzerland). Distal 
colon tissues (25 mg) were placed in RPMI 1640 medium (Thermo Fisher Scientific) 
with 10% fetal bovine serum (FBS, EMD Millipore, Temecula, CA) supplemented with 
penicillin (100 U/mL) and streptomycin (100 μg/mL), and incubated at 37 °C in an 
atmosphere containing 5% CO2 for 24 h. The supernatants were collected, and cytokines 
in the supernatant were measured by the CBA Mouse Inflammation Kit (BD Biosciences) 
according to the manufacturer’s instruction.  
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4.2.8 Hematoxylin and Eosin (H&E) staining 
Dissected colon tissues were cut open longitudinally, washed in ice-cold PBS and 
fixed in 4% formalin (Thermo Fisher Scientific) at 4 °C. Tissues were gradually 
incubated with 15% and 30% sucrose (Thermo Fisher Scientific) at 4 °C, then embedded 
in optimal cutting temperature (OCT) compound (Fisher Healthcare, Houston, TX) and 
frozen for cryosectioning. OCT-fixed tissue specimens were sliced into 5 μm sections, 
mounted on glass slides, and air-dried for one hour. Sections were stained with H&E 
staining (Sigma-Aldrich) and examined with light microscopy. The histological scores 
were evaluated by a blinded observer and given scores according to the following 
measures: crypt architecture (scored 0-3 with 0 as normal and 3 as most crypt distortion 
and loss); inflammatory cell infiltration (0-3 with 0 as normal and 3 as most dense 
inflammatory infiltrate); muscle thickening (0-3 with 0 as normal and 3 being most 
muscle thickness); goblet cell depletion (0-1 with 0 as goblet cells present and 1 goblet 
cells depleted) and crypt abscess (0-1 with 0 as absent and 1 present). The histological 
score is the sum of each score.  
4.2.9 Immunohistochemistry  
Formalin-fixed tissue was embedded in paraffin by using TissueWave™ 2 
Microwave Processor (Thermo Fisher Scientific), sliced to 5 µm sections on the same 
slide, dewaxed in serial xylene solutions (Thermo Fisher Scientific), and rehydrated 
through graded ethanol solutions (Pharmco-Aaper, Shelbyville, KY). Antigen retrieval 
was performed by heating the sections in 0.01 M citrate buffer (pH 6.0) to 95°C for 10 
minutes. Samples were incubated with anti-PCNA antibody (Dako, Carpinteria, CA), 
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anti-cleaved caspase-3 antibody (Cell Signaling Technology, Danvers, MA), anti-β-
catenin antibody (BD Biosciences) overnight at 4 °C. Horseradish peroxidase (HRP)-
conjugated secondary antibodies were then applied to the sections, followed by the 
chromogen 4-diaminobenzidine staining according to the instruction of HRP/DAB 
(ABC) Detection IHC kit (Abcam, Cambridge, MA). Sections were then counterstained 
with hematoxylin for 1 min. Positive expression of PCNA, cleaved caspase-3 and β-
catenin were observed under light microscope and scored using Fiji software 183. Briefly, 
images of the IHC stained tissues were uploaded to Fiji, and the color was deconvoluted. 
The intensity numbers of the “Colour_2” image (brown staining) were converted to 
Optical Density (OD) numbers and then scored relative to control.  
 
4.2.10 Quantitative reverse-transcriptase DNA polymerase chain reaction (qRT-
PCR) analysis 
Distal colon tissues (20 mg) were ground using liquid nitrogen. Total RNA was 
isolated from the colon tissues using TRIzol reagent (Ambion, Austin, TX) according to 
the manufacturer’s instructions. The RNA was reverse transcribed into cDNA using a 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) 
according to manufacturer’s instructions. qRT-PCR was carried out with a DNA Engine 
Opticon system (Bio-Rad Laboratories, Hercules, CA) with PowerUpTM SYBRTM Green 
Master Mix (Thermo Fisher Scientific). The sequences of mouse-specific primers 
(Thermo Fisher Scientific) are listed in Table 4.2. Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) expression was used as an internal control. 
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4.2.11 Toll-like receptor 4 (TLR4) reporter cell assay 
HEK-Blue™ mTLR4 cells (InvivoGen, San Diego, CA) were cultured in DMEM 
medium supplemented with 10% FBS and HEK-Blue™ Selection solution (InvivoGen, a 
mixture of antibiotics to maintain the expression of transgenes in HEK-Blue™ mTLR4 
cells) and incubated in a 37 °C incubator under an atmosphere of 5% CO2, according to 
the manufacturer’s instructions. Briefly, to determine activation of TLR4, 20 μL of 
mouse plasma sample, and 180 μL of 2 x 104 HEK-Blue™ mTLR4 cells suspended in 
HEK-BlueTM Detection medium, was added into each well of 96-well plate. After 
incubation at 37 oC for 16 h, the production of secreted embryonic alkaline phosphatase 
(SEAP) was assessed by reading the absorbance at 620 nm with a plate reader (Molecular 
Devices, Sunnyvale, CA). 
4.2.12 Quantification of LPS in plasma 
Plasma LPS levels were quantified using the LPS ELISA kit (MBS261904, 
MyBiosource, San Diego, CA) following the manufacturer’s instructions. 
4.2.13 Real-time PCR (qPCR) analysis of 16S rRNA gene in liver  
DNA was extracted from mouse liver samples (~25 mg) using QIAamp DNeasy 
Blood & Tissue Kit (Qiagen, Valencia, CA) following the manufacturer’s instruction 
with the addition of the bead-beating step. The quality of the extracted DNA was 
measured using a NanoDrop Spectrophotometer (Thermo Fisher Scientific). DNA was 
subjected to qPCR analysis using a DNA Engine Opticon system (Bio-Rad Laboratories, 
Hercules, CA) with PowerUpTM SYBRTM Green Master Mix (Thermo Fisher Scientific).  
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DNA was normalized to 5 ng/μL per reaction. The sequences the 16S rRNA primers 
(Thermo Fisher Scientific) are listed in Table 4.2. 
4.2.14 Data analysis 
Data are expressed as the mean ± standard error of the mean (SEM). Group 
comparisons were carried out using one-way analysis of variance (ANOVA) or Student t-
test. P values less than 0.05 were considered statistically significant.  
4.3 Results 
4.3.1 Exposure to BAC and BET exaggerated DSS-induced colitis in mice 
To study the effects of these antimicrobials on colonic inflammation, we used a 
well-established DSS-induced colitis model in mice. We treated mice with BAC, BET, 
PCMX (80 ppm in the diet), or vehicle via diet for 21 days. During this period, treatment 
with the antimicrobial alone did not affect the mouse body weight (Figure 4.1). We then 
stimulated the mice with 2% DSS in drinking water for 7 days to induce colonic 
inflammation (see scheme of animal experiment in Figure 4.2). 
Exposure to BAC and BET, but not PCMX, increased DSS-induced colonic 
inflammation in mice. Compared with vehicle-treated DSS mice, the BAC-treated DSS 
mice showed increased weight loss on days 6-7 after initiation of DSS stimulation (P < 
0.05), while BET and PCMX had no such effect (Figure 4.2B). Exposure to all three 
antimicrobial compounds caused a reduction in colon length (P < 0.001, Figure 4.2C), 
which is a biomarker of colitis. Histology analysis showed that exposure to BAC and 
BET, but not PCMX, increased DSS-induced colonic inflammation, with increased crypt 
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damage and inflammatory cell infiltration into colon tissues (P < 0.05, Figure 4.2D). We 
next analyzed the colon at the cellular and molecular level. Immune cells and cytokines 
play critical roles in the development of colitis 2. Flow cytometry analysis showed that 
exposure to BAC and BET, but not PCMX, increased infiltration of immune cells–
including leukocytes (CD45+), macrophages (CD45+, F4/80+), and neutrophils (CD45+, 
Gr1+)–into colon tissues (P < 0.05, Figure 4.2E). ELISA analysis showed that exposure 
to BAC and BET, but not PCMX, increased concentrations of interleukin 6 (IL-6), a pro-
inflammatory cytokine, in colonic explant (P < 0.05, Figure 4.2F). Consistent with the 
ELISA result, qRT-PCR analysis showed that exposure to BAC increased gene 
expression of Il-6 in colon tissues (P < 0.01); BET also increased Il-6 expression, but the 
effect was not statistically significant, and PCMX had no effect (Figure 4.2G). These 
results suggest that BAC and BET, but not PCMX, were able to increase DSS-induced 
colonic inflammation. 
4.3.2 Dose-dependent effects of BAC on DSS-induced colitis in mice 
Among the three compounds, BAC showed the most potent effect on DSS-
induced colonic inflammation, and we further studied its dose-dependent effect on 
colonic inflammation (see scheme of animal experiment in Figure 4.3A). The results 
showed that exposure to 20-40 ppm of BAC in the diet (~2-4 mg/kg body weight/day) 
caused a reduction in colon length (P < 0.05, Figure 4.3B).  Flow cytometry analysis 
showed that exposure to BAC increased immune cell infiltration into the colon in a dose-
dependent manner (Figure 4.3C). These results suggest that even at lower doses, BAC 
was able to increase DSS-induced colonic inflammation.  
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4.3.3 Exposure to BAC exaggerated AOM/DSS-induced colon tumorigenesis in 
mice 
After demonstrating that exposure to BAC showed the most potent effect on DSS-
induced colonic inflammation, we studied its effect on colitis-associated colon 
tumorigenesis using an AOM/DSS-induced colon tumorigenesis model in mice (see 
scheme of animal experiment in Figure 4.4A). Compared with vehicle-treated mice, the 
mice treated with BAC had increased mortality: the overall mortality for the control 
group was 21% (3 out of 14 mice died in the control group), and mortality for the BAC 
group was 60% (9 out of 15 mice died in BAC group) (Figure 4.4B). Exposure to BAC 
increased the spleen weight, suggesting increased systemic inflammation: the spleen 
weight of vehicle-treated mice was 135 ± 14 mg (mean ± SEM) versus 191 ± 20 mg for 
BAC-treated mice (P < 0.05, Figure 4.4C). Exposure to BAC also increased the average 
tumor size (1.8 ± 0.3 cm2 for the control group versus 3.5 ± 0.5 cm2 for the BAC group, P 
= 0.008), yet had no effect on the numbers of tumors per mouse (8.6 ± 1.3 for the control 
group versus 10 ± 1.8 for the BAC group, P = 0.539), although the total tumor burden in 
mice did increase (14.8 ± 3.7 cm2 for the control group versus 35 ± 8.8 cm2 for BAC 
group, P = 0.033) (Figure 4.4D). The qRT-PCR analysis showed that treatment with 
BAC increased the gene expressions of several pro-tumorigenic genes, such as c-Jun, 
cyclin D, and β-catenin, in colon tumors (P < 0.05, Figure 4.4E). Consistent with the 
qRT-PCR result, immunohistochemistry showed that β-catenin protein levels were 
increased in colon tumors of BAC-treated mice (P < 0.01). In addition, we found that the 
proliferating cell nuclear antigen (PCNA) protein levels were increased (P < 0.01), while 
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cleaved caspase-3 protein levels were decreased (P<0.001), in BAC-treated colon tumors, 
which suggests that exposure to BAC increased tumor proliferation and decreased tumor 
apoptosis (Figure 4.4F). Together, these results demonstrate that exposure to BAC 
increased AOM/DSS-induced colitis-associated colon tumorigenesis in mice. 
4.3.4 Exposure to BAC increased activation of Toll-like receptor 4 (TLR4) in 
systemic circulation 
Innate immunity receptors, in particular TLR4, play critical roles in regulating 
colonic inflammation and associated colon tumorigenesis 184,185. We studied the effects of 
BAC exposure on TLR4 signaling, by testing the potential of the plasma from BAC-
treated DSS mice on the activation of TLR4. Using a TLR4 reporter cell line (HEK-
Blue™ mTLR4), we found that, compared with the plasma from vehicle-treated DSS 
mice, the plasma from BAC-treated DSS mice caused enhanced activation of TLR4 (P = 
0.013, Figure 4.5A). Consistent with the TLR4 reporter assay, we found that the BAC-
treated DSS mice had higher plasma levels of LPS, a known ligand of TLR4 (P = 0.040, 
Figure 4.5B) 186. In addition, we found that the liver tissues from BAC-treated DSS mice 
had higher levels of bacterial DNA, as assessed by qPCR analysis of 16S rRNA gene (P = 
0.064, Figure 4.5C). These results demonstrate that exposure to BAC enhanced 
translocation of bacterial products from the gut into the circulation and other organs. 
Previous studies showed that an enhanced level of bacterial products in the systemic 
circulation could be due to compromised mucosal permeability 187. Therefore, we tested 
the effect of BAC exposure on the expression of colonic proteins involved in regulating 
intestinal barrier function. We found that compared with vehicle-treated DSS mice, the 
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BAC-treated DSS mice had a dramatic reduction of colonic expression of  Occludin (P = 
0.006, Figure 4.5D), which encodes a protein that plays an important role in maintaining 
mucosal barrier function 188. Together, these results showed that exposure to BAC 
enhanced activation of TLR4 in the systemic circulation, in part through impairing 
intestinal barrier function and enhancing bacterial products in the circulation.    
4.4 Discussion 
In the last century, there has been a dramatic increase in the incidence and 
prevalence of IBD in the United States and other countries 1. This rapid development 
suggests that environmental factors could contribute to the growing incidence of IBD 
around the globe 3-5. In support of this hypothesis, recent studies showed that exposure to 
certain dietary and environmental compounds increased the development of IBD in 
animal models 4,5. Due to the increased incidences of IBD and the potential lethal 
consequence of IBD-associated colon cancer, it is of practical importance to discover 
new environmental risk factors for these diseases.  
BAC, BET, and PCMX are antimicrobial compounds used in many consumer 
products. Previous studies showed that these compounds could cause some adverse 
effects, including inflammatory responses and genotoxic effects 83-85,179, mitochondrial 
dysfunction 180, reproductive dysfunction 81, and developmental defects 181. In this study, 
we studied their effects on IBD and IBD-associated colon tumorigenesis in mouse 
models. Here, our central finding is that short-term exposure to low-dose antimicrobial 
compounds, in particular BAC and BET, increased colitis and/or colitis-associated colon 
tumorigenesis in mice, which suggests potential adverse effects from these compounds. 
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Among the tested three compounds, PCMX showed the least severe adverse effect; 
however, in the DSS colitis experiment, exposure to PCMX also increased DSS-induced 
colon length reduction. This suggests some adverse effects on gut health may result from 
PCMX. Our results are in agreement with previous studies that illustrated pro-
inflammatory effects of BAC in vitro. These studies showed that treatment with BAC 
increased production of pro-inflammatory cytokines in immortalized human conjunctival 
and corneal epithelial cells, and increased phagocytosis, macrophage migration, and 
production of pro-inflammatory cytokines in THP-1-derived macrophages 83,84. 
Therefore, the enhancing effects of BAC on colitis and colitis-associated colon cancer 
could be, at least in part, due to its pro-inflammatory effect. To our knowledge, this study 
is the first animal study to demonstrate that these antimicrobial compounds have adverse 
effects on gut health. A better understanding of their actions on colonic inflammation and 
colon cancer could help to establish regulatory policies for these compounds.  
Among the three tested antimicrobial compounds, PCMX showed the least 
adverse effect on DSS-induced colitis, with little impact on colonic inflammation. There 
could be several reasons for the different effects of PCMX compared to BAC and BET. 
PCMX, but not BAC and BET, contains a phenolic group, which is highly prone to rapid 
metabolism by phase II detoxification enzymes such as glucuronosyltransferase and 
sulfotransferase, leading to formation of water-soluble conjugated metabolites 
(glucuronides and sulfates) and excretion via the urine. Indeed, previous studies in dogs 
showed that PCMX was rapidly metabolized to glucuronide- and sulfate- conjugates and 
excreted in urine 189. Therefore, the lack of effect of PCMX on colonic inflammation in 
our studies could be in part due to its poor metabolic stability. In addition, compared with 
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BAC and BET, PCMX has a much smaller size, which could impact its absorption and 
duration in the gastrointestinal tract. To date, the metabolism and pharmacokinetics of 
these antimicrobial compounds in vivo are not well investigated. Further studies could 
help to address the structure-activity relationships of the antimicrobials, which could help 
to design better antimicrobial ingredients.    
A critical question in this study is whether the effects observed in the animal 
models represent responses that would arise from human exposure. An examination of 
the comparability of our administered dosage to investigated Acceptable Daily Intake 
(ADI) levels can shed light on this question. In our experiment, we found that exposure to 
40 ppm of BAC in diet (administering BAC at a dose of ~4 mg/kg/day, based on a diet of 
3 g daily chow) increased colitis-associated colon tumorigenesis in mice. The dose used 
in our animal experiment is the lowest among reported animal studies of BAC 42,190. To 
put the dose in perspective, previous studies showed that the No-Observed-Adverse-
Effect Level (NOAEL) of BAC was 192 mg/kg body weight/day from a 90-day study in 
CD-1 mice 191, which leads to a calculated ADI of BAC of ~1.9 mg/kg body weight/day 
192. Therefore, the dose of BAC used in the animal experiments is comparable to 
previously investigated ADI values. This supports the biological relevance of our 
findings. We recognize the difficulties in translating the animal data to human studies. 
There are several challenges to using animal models to study human exposure to these 
consumer antimicrobial compounds. First, accurate assessment of the degree, type, and 
variation of exposure levels of these compounds in humans is largely lacking. Second, 
dermal exposure (e.g. by using soaps) and oral exposure (e.g. by using mouthwash or 
toothpaste) to these antimicrobial compounds could lead to different biological responses. 
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Indeed, a recent study showed that usage of antibacterial toothpaste, but not antibacterial 
soaps, modulated gut microbiota in humans 193. Third, after exposure to these 
compounds, there could be a high degree of inter-individual variation in the metabolism 
and secretion of these compounds. Based on our studies, it is feasible to conclude that 
long-term high-dose exposure to these antimicrobial compounds could lead to adverse 
effects on gut health. Previous studies have shown that BAC and BET were frequently 
detected at high levels in grapefruit seed extract (GSE), a popular dietary supplement, 
despite the fact that these compounds are not permitted to use as food additives 37,38. 
Notably, von Woedtke et al. showed that five out of six commercial GSE products 
contained 1.3-10% of BET. Frequent consumption of these contaminated dietary products 
could lead to high-dose exposure to BET and might cause adverse effects on gut health.  
TLRs are important innate immunity receptors and play critical roles in regulating 
colonic inflammation and associated colon tumorigenesis 2,194. Our results showed that 
during DSS-induced colitis, exposure to BAC impaired intestinal barrier function and 
thus enhanced translocation of bacterial products (e.g. LPS and bacteria) from the gut 
into the systemic circulation and other organs, resulting in enhanced activation of TLR4 
in the systemic circulation. Previous studies showed that enhanced activation of TLR4 is 
associated with increased progression of colitis and colitis-associated colon cancer 
185,195,196. Indeed, compared with WT mice, genetically-engineered mice lacking TLR4 
had attenuated, while genetically-engineered mice with overexpression of TLR4 had 
enhanced, the progression of DSS-induced colitis and/or AOM/DSS-induced colon 
cancer 184,195,196, though there are inconsistent results 197. Together, these results support 
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that TLR4 signaling might play a role in the observed pro-colitis and pro-neoplastic 
effects of BAC.  
In summary, our study showed that exposure to low-dose antimicrobial 
compounds, particularly BAC, increased colonic inflammation and colon cancer in mice. 
These studies suggest that further studies are needed to better characterize the effects of 
these compounds on gut health in order to develop sound regulatory policies for these 
compounds. 
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Table 4.1. Composition of the modified AIN-93G diet used in the animal 
experiments. 
 
Ingredients g/kg 
Casein 200 
L-cystine 3 
Sucrose 100 
Dyetrose 132 
Cornstarch 397.486 
Cellulose 50 
Mineral mix #210025 35 
Vitamin mix #310025 10 
Choline bitartrate 2.5 
Corn oil (purified) * 70 
Vitamin A palmitate 0.016 
* All ingredients, except corn oil, were purchased from Dyets Inc (Bethlehem, PA). Because 
commercial corn oil was already oxidized with varied degrees of lipid peroxidation, we used 
purified corn oil for our animal experiments. Briefly, commercial corn oil was purchased from a 
local market in Amherst, MA, and purified by a silicic acid-activated charcoal chromatography to 
remove any pre-existing oxidized compounds 198, then the purified oil was fortified with 400 ppm 
tocopherols, flushed with N2, and stored at -80°C until use.  
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Table 4.2. Sequences of primers in qRT-PCR and qPCR. 
 
Gene Forward Reverse 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Tlr4 ATGGCATGGCTTACACCACC GAGGCCAATTTTGTCTCCACA 
Axin2 TGCATCTCTCTCTGGAGCTG ACTGACCGACGATTCCATGT 
C-Jun CCTTCTACGACGATGCCCTC GGTTCAAGGTCATGCTCTGTTT 
Ki67 ATCATTGACCGCTCCTTTAGGT GCTCGCCTTGATGGTTCCT 
C-myc TGAAGTTCACGTTGAGGGG AGAGCTCCTCGAGCTGTTTG 
CyclinD GCGTACCCTGACACCAATCTC  CTCCTCTTCGCACTTCTGCTC 
Wnt2 CTCGGTGGAATCTGGCTCTG CACATTGTCACACATCACCCT 
β-catenin   CAGCTTGAGTAGCCATTGTCC GAGCCGTCAGTGCAGGAG 
Occludin   ACGGACCCTGACCACTATGA TCAGCAGCAGCCATGTACTC 
16S rRNA 
 
TCGTCGGCAGCGTCAGATGTGTAT 
AAGAGACAGCCTACGGGNGGCWGC
AG 
GTCTCGTGGGCTCGGAGATGTGTATA 
AGAGACAGGACTACHVGGGTATCTAA
TCC 
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Figure 4.1. Effect of BAC, BET, and PCMX on mice body weight.  
The results are expressed as mean ± SEM. 
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Figure 4.2. Effects of BAC, BET, and PCMX on DSS-induced colitis in C57BL/6 
mice.  
(A) Scheme of animal experiment. (B) Body weight. (C) Colon length. (D) 
Representative images of H&E staining of colon sections and histological score. (E) 
Quantification of immune cell infiltration into colon tissues. (F) ELISA analysis of IL-6 
in colonic explant. (G) Gene expression of Il-6 in colon tissues. The results are expressed 
as mean ± SEM, n = 12 mice per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 4.3. Dose-response effect of BAC on DSS-induced colonic inflammation in 
mice.  
(A) Scheme of animal experiment. (B) Colon length. (C) Flow cytometry analysis of 
immune cells in colon tissues. The results are expressed as mean ± SEM, n = 8 mice per 
group, * P < 0.05, ** P < 0.01. 
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Figure 4.4. Effect of BAC on AOM/DSS-induced colitis-associated colon cancer in 
C57BL/6 mice.  
(A) Scheme of animal experiment. (B) Survival rate. (C) Spleen weight. (D) 
Representative images of colon tumors and quantification of colon tumorigenesis. (E) 
qRT-PCR analysis of gene expressions in colon tumors. (F) Representative images of 
immunohistochemical staining (magnification ×300) of β-catenin, PCNA, cleaved 
caspase 3, and H&E, and quantification of immunohistochemical images. The results are 
expressed as mean ± SEM, n = 14-15 mice per group, * P < 0.05, ** P < 0.01, *** P < 
0.001. 
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Figure 4.5. BAC exposure increased TLR4 activation in the systemic circulation.  
(A) TLR4 reporter assay of the plasma from BAC- or vehicle-treated DSS mice. (B) 
Concentration of LPS in plasma. (C) Expression of 16S rRNA gene in liver. (D) qRT-
PCR analysis of gene expression of Occludin in colon. The results are expressed as mean 
± SEM, n = 10-12 mice per group. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
IBD has become a serious health problem since its incidence and prevalence has 
dramatically increased throughout the world. Antimicrobials used in consumer products 
might serve as environmental risk factors for IBD and its associated diseases. TCS, TCC, 
BAC, BET, and PCMX are widely used antimicrobial ingredients in consumer products 
and are ubiquitous contaminants in the environment. In 2016, the FDA removed TCS and 
TCC from over-the-counter handwashing products while allowing additional time to 
develop new safety and efficacy data for BAC, BET, and PCMX. Therefore, it is 
important and timely to better understand the effects of these antimicrobials on human 
health. Currently, there is not much known about how chronic exposure to low-dose 
consumer antimicrobials affects gut health. Here, we validated the effects and 
mechanisms of triclosan, as well as other consumer antimicrobials, and the gut 
microbiome on IBD using three studies. 
First, we showed that TCS was metabolically re-activated in the gut by the actions 
of gut microbiota, leading to the accumulation of microbiota-derived toxic metabolites in 
the colon and resulting in gut-specific toxicity. Upon TCS exposure, the dominant 
metabolites of TCS in host tissues were its glucuronide- and sulfate- conjugates, which 
are biologically inactive; however, in the colon digesta, the dominant metabolites were 
free-form TCS species, which have potent and direct effects on both colon epithelial cells 
and gut bacteria to induce a pro-inflammatory phenotype. This unique profile of TCS 
metabolism in the colon digesta was disrupted by treatment with an antibiotic cocktail. 
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Furthermore, gut microbiota from mice and humans, as well as specific bacteria strains 
(Lactobacillus brevis, L. rhamnosus, and Bifidobacterium breve), catalyzed TCS 
biotransformation in vitro, supporting that gut microbiota mediates TCS metabolism.  
Second, we showed that exposure to low-dose TCC exaggerated the severity of 
colitis and exacerbated the development of colitis-associated colon tumorigenesis, via gut 
microbiota-dependent mechanisms. Exposure to TCC increased DSS- and IL-10 
knockout- induced colitis, and exaggerated AOM/DSS-induced colon tumorigenesis in 
mice. Regarding its mechanisms, TCC exposure reduced the diversity, altered the 
composition of gut microbiota, and failed to promote DSS-induced colitis in mice lacking 
the microbiota, supporting that the presence of the microbiota is critical for the pro-colitis 
effects of TCC.  
Finally, we reported that exposure to low doses of BAC, BET, and PCMX increased 
DSS-induced colonic inflammation, and BAC increased AOM/DSS-induced colon 
tumorigenesis in mice. In addition, we find that exposure to BAC increases activation of 
TLR4 signaling in the systemic circulation, by disrupting intestinal barrier function and 
thus enhancing circulating levels of bacterial products.  
Our studies support that the gut microbiome is required for the pro-inflammatory 
effects of these antimicrobials. However, the functional roles of the microbiome, as well 
as the specific gut bacteria, involved in the biological actions of these antimicrobials are 
unknown. Elucidation of the specific bacteria involved will help to design human studies 
to validate the impact of antimicrobial exposure on human health and clarify potential 
inter-individual variations in metabolism and responses to their exposure. 
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The regulatory policy of TCS, as well as other antimicrobials, is an intensively 
debated topic now. Our study, as well as the research from other laboratories, support that 
TCS and other widely-used antimicrobials could have adverse effects on the gut 
microbiome and gut health. More studies are needed to better characterize the impact of 
these compounds on gut health in humans. 
There are still more experiments needed to evaluate TCS on gut health. In our 
study, we treated mice with TCS, and other antimicrobials, for several weeks. Because 
humans could potentially be exposed to TCS for many years, it is worth pursuing an 
animal study exposing mice for several months, or longer to further mimic human 
exposure to TCS. This would be especially interesting due to the fact that we see 
dramatically enhanced colon damage (>2-fold in the histological score) in mice exposed 
to TCS for only a relatively short time of 3 weeks 121. In addition to exposing mice for a 
longer period, another potential experiment is to expose mice to TCS for a few weeks and 
then stop exposure for another several weeks to see if this removal of TCS would 
decrease TCS-enhanced colitis. This is based a previous study which showed that the 
modulation of the gut microbiomes of TCS-exposed and unexposed fathead minnows 
disappeared after 2 weeks of depuration 116; this suggests that the modulation caused by 
TCS may disappear after removal of TCS, which may in turn lead to a decrease in TCS-
enhanced colitis. 
It would be ideal to further investigate the identification of which specific bacteria 
contribute to TCS-enhanced colitis, and whether this is due to TCS promoting 
antibacterial resistance in specific microbes. There has been concern of TCS promoting 
antibacterial resistance in specific microbes 199, and some of the studies previously 
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discussed support this: in zebrafish, the abundance of microbes that are resistant to TCS 
was increased in the TCS-exposed groups 117;  in infants, there was a positive correlation 
between urinary TCS levels and Proteobacteria species which is a group associated with 
an increase in antibiotic resistance genes in the gut microbiota 65; and in mice, TCS also 
appeared to enrich genes in bacteria that are involved in TCS resistance, multidrug 
resistance efflux pumps, and bacterial stress when exposed to mice 8. 
Together, our results suggest that these widely used antimicrobial compounds could 
exaggerate disease development of inflammatory bowel disease and associated colon 
cancer. Further studies are urgently needed to better characterize the impacts of these 
compounds on gut diseases in order to develop sound regulatory policies for these 
compounds. 
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